Muscle-invasive and Metastatic Bladder Cancer

Guidelines Associates: E. Linares Espinós, M. Rouanne, Y. Neuzillet
TABLE OF CONTENTS

1. INTRODUCTION 6
   1.1 Aims and scope 6
   1.2 Panel composition 6
   1.3 Available publications 6
   1.4 Publication history and summary of changes 6
      1.4.1 Publication history 6
      1.4.2 Summary of changes 6

2. METHODS 9
   2.1 Data identification 9
   2.2 Peer-review 10
      2.2.1 Lay review 10
   2.3 Future goals 11

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY 11
   3.1 Epidemiology 11
   3.2 Aetiology 11
      3.2.1 Tobacco smoking 11
      3.2.2 Occupational exposure to chemicals 11
      3.2.3 Radiotherapy 11
      3.2.4 Dietary factors 12
      3.2.5 Metabolic disorders 12
      3.2.6 Bladder schistosomiasis and chronic urinary tract infection 12
      3.2.7 Gender 12
      3.2.8 Genetic factors 13
      3.2.9 Summary of evidence and guidelines for epidemiology and risk factors 13
   3.3 Pathology 13
      3.3.1 Handling of transurethral resection and cystectomy specimens 13
      3.3.2 Pathology of muscle-invasive bladder cancer 14
      3.3.3 Guidelines for the assessment of tumour specimens 14
      3.3.4 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer 15

4. STAGING AND CLASSIFICATION SYSTEMS 15
   4.1 Pathological staging 15
   4.2 Tumour, node, metastasis classification 15

5. DIAGNOSTIC EVALUATION 16
   5.1 Primary diagnosis 16
      5.1.1 Symptoms 16
      5.1.2 Physical examination 16
      5.1.3 Bladder imaging 16
      5.1.4 Urinary cytology 16
      5.1.5 Cystoscopy 16
      5.1.6 Transurethral resection of invasive bladder tumours 17
      5.1.7 Concomitant prostate cancer 17
      5.1.8 Summary of evidence and guidelines for the primary assessment of presumably invasive bladder tumours 17
      5.1.9 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer 18
   5.2 Imaging for staging of MIBC 18
      5.2.1 Local staging of MIBC 18
         5.2.1.1 CT imaging for local staging of MIBC 19
      5.2.2 Imaging of lymph nodes in MIBC 19
      5.2.3 Upper urinary tract urothelial carcinoma 19
         5.2.3.1 Computed tomography urography 19
         5.2.3.2 Magnetic resonance urography 19
      5.2.4 Distant metastases at sites other than lymph nodes 19
5.2.5 Future developments
5.2.6 Summary of evidence and guidelines for staging in muscle-invasive bladder cancer

5.3 MIBC and health status
5.3.1 Evaluation of comorbidity, frailty and cognition
5.3.2 Comorbidity scales, anaesthetic risk classification and geriatric assessment
5.3.3 Summary of evidence and guidelines for comorbidity scales

6. MARKERS
6.1 Introduction
6.2 Prognostic markers
6.2.1 Histopathological and clinical markers
6.2.2 Molecular markers
6.2.2.1 Molecular subtypes based on the Cancer Genome Atlas cohort

6.3 Predictive markers
6.3.1 Clinical and histopathological markers
6.3.2 Molecular markers

6.4 Conclusion
6.5 Summary of evidence and recommendations for urothelial markers

7. DISEASE MANAGEMENT
7.1 Neoadjuvant therapy
7.1.1 Introduction
7.1.2 Role of cisplatin-based chemotherapy
7.1.2.1 Summary of available data
7.1.3 The role of imaging and predictive biomarkers
7.1.4 Role of neoadjuvant immunotherapy
7.1.5 Summary of evidence and guidelines for neoadjuvant therapy

7.2 Pre- and post-operative radiotherapy in muscle-invasive bladder cancer
7.2.1 Post-operative radiotherapy
7.2.2 Pre-operative radiotherapy
7.2.3 Summary of evidence and guidelines for pre- and post-operative radiotherapy
7.2.4 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer

7.3 Radical surgery and urinary diversion
7.3.1 Removal of the tumour-bearing bladder
7.3.1.1 Introduction
7.3.1.2 Radical cystectomy: timing
7.3.2 Radical cystectomy: indications
7.3.3 Radical cystectomy: technique and extent
7.3.3.1 Radical cystectomy in men
7.3.3.1.1 Summary of evidence and recommendations for sexual-preserving techniques in men
7.3.3.2 Radical cystectomy in women
7.3.3.2.1 Summary of evidence and recommendations for sexual-preserving techniques in women

7.3.4 Lymphadenectomy: role and extent
7.3.5 Laparoscopic/robotic-assisted laparoscopic cystectomy
7.3.5.1 Laparoscopic radical cystectomy versus robot-assisted radical cystectomy
7.3.5.2 Summary of evidence and guidelines for laparoscopic/robotic-assisted laparoscopic cystectomy

7.3.6 Urinary diversion after radical cystectomy
7.3.6.1 Patient selection and preparations for surgery
7.3.6.2 Different types of urinary diversion
7.3.6.2.1 Uretero-cutaneostomy
7.3.6.2.2 Ileal conduit
7.3.6.2.3 Orthotopic neobladder

7.3.7 Morbidity and mortality
7.3.8 Survival
7.3 Impact of hospital and surgeon volume on treatment outcomes 39
  7.3.9 Summary of evidence and guidelines for radical cystectomy and
  urinary diversion 40
  7.3.11 EAU-ESMO consensus statements on the management of advanced-
  and variant bladder cancer 41

7.4 Unresectable tumours 42
  7.4.1 Palliative cystectomy for muscle-invasive bladder carcinoma 42
    7.4.1.1 Guidelines for unresectable tumours 42
    7.4.1.2 EAU-ESMO consensus statements on the management of advanced-
    and variant bladder cancer 42
  7.4.2 Supportive care 42
    7.4.2.1 Obstruction of the upper urinary tract 42
    7.4.2.2 Bleeding and pain 42

7.5 Bladder-sparing treatments for localised disease 42
  7.5.1 Transurethral resection of bladder tumour 42
    7.5.1.1 Guideline for transurethral resection of bladder tumour 43
    7.5.1.2 EAU-ESMO consensus statements on the management of advanced-
    and variant bladder cancer 43
  7.5.2 External beam radiotherapy 43
    7.5.2.1 Summary of evidence and guideline for external beam radiotherapy 44
    7.5.2.2 EAU-ESMO consensus statements on the management of advanced-
    and variant bladder cancer 44
  7.5.3 Chemotherapy 44
    7.5.3.1 Summary of evidence and guideline for chemotherapy 44
  7.5.4 Trimodality bladder-preserving treatment 45
    7.5.4.1 Summary of evidence and guidelines for trimodality bladder-
    preserving treatment 46
    7.5.4.2 EAU-ESMO consensus statements on the management of advanced-
    and variant bladder cancer 47

7.6 Adjuvant therapy 47
  7.6.1 Role of adjuvant platinum-based chemotherapy 47
  7.6.2 Role of adjuvant immunotherapy 48
  7.6.3 Guidelines for adjuvant therapy 48

7.7 Metastatic disease 48
  7.7.1 Introduction 48
    7.7.1.1 Prognostic factors and treatment decisions 48
    7.7.1.2 Comorbidity in metastatic disease 49
  7.7.2 First-line systemic therapy for metastatic disease 49
    7.7.2.1 Definitions: ‘Fit for cisplatin, fit for carboplatin, unfit for any platinum-
    based chemotherapy’ 49
    7.7.2.2 Chemotherapy in patients fit for cisplatin 49
    7.7.2.3 Chemotherapy in patients fit for carboplatin (but unfit for cisplatin) 50
    7.7.2.4 Integration of immunotherapy in the first-line treatment of patients fit
    for platinum-based chemotherapy 50
      7.7.2.4.1 Immunotherapy combination approaches 50
      7.7.2.4.2 Use of single-agent immunotherapy 50
      7.7.2.4.3 Switch maintenance with immunotherapy 51
    7.7.2.5 Treatment of patients unfit for any platinum-based chemotherapy 51
    7.7.2.6 Non-platinum combination chemotherapy 51
  7.7.3 Second-line systemic therapy for metastatic disease 51
    7.7.3.1 Second-line chemotherapy 51
    7.7.3.2 Second-line immunotherapy for platinum-pre-treated patients 52
      7.7.3.2.1 Side-effect profile of immunotherapy 52
    7.7.4 Novel agents for second- or later-line therapy 52
  7.7.5 Post-chemotherapy surgery and oligometastatic disease 53
  7.7.6 Treatment of patients with bone metastases 53
  7.7.7 Summary of evidence and guidelines for metastatic disease 54

7.8 Quality of life 55
  7.8.1 Introduction 55
  7.8.2 Neoadjuvant chemotherapy 55
7.8.3 Radical cystectomy and urinary diversion 56
7.8.4 Bladder sparing trimodality therapy 56
7.8.5 Non-curative or metastatic bladder cancer 56
7.8.6 Summary of evidence and recommendations for health-related quality of life 56

8. FOLLOW-UP 57
8.1 Follow-up in muscle invasive bladder cancer 57
8.2 Site of recurrence 57
8.2.1 Local recurrence 57
8.2.2 Distant recurrence 57
8.2.3 Urothelial recurrences 58
8.3 Time schedule for surveillance 58
8.4 Follow-up of functional outcomes and complications 58
8.5 Summary of evidence and recommendations for specific recurrence sites 59
8.6 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer 59

9. REFERENCES 60

10. CONFLICT OF INTEREST 94

11. CITATION INFORMATION 94
1. INTRODUCTION

1.1 Aims and scope
The European Association of Urology (EAU) Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) have prepared these guidelines to help urologists assess the evidence-based management of MIBC and to incorporate guideline recommendations into their clinical practice.

Separate EAU guidelines documents are available addressing upper urinary tract (UUT) tumours [1], non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) (NMIBC) [2], and primary urethral carcinomas [3].

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition
The EAU Guidelines Panel consists of an international multidisciplinary group of clinicians, including urologists, oncologists, a pathologist, a radiologist and radiotherapists. Section 5.3 -MIBC and health status, was developed with the assistance of Dr. S. O’Hanlon, consultant geriatrician, International Society of Geriatric Oncology (SIOG) representative and member of the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. The MIBC Panel is most grateful for his support.

All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: http://uroweb.org/guideline/bladdercancermuscle-invasive-and-metastatic/?type=panel.

1.3 Available publications
A quick reference document (Pocket Guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version.

Several scientific publications are available (the most recent paper dating back to 2020 [4]), as are a number of translations of all versions of the EAU MIBC Guidelines. All documents are accessible through the EAU website: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.

1.4 Publication history and summary of changes
1.4.1 Publication history
The EAU published its first guidelines on bladder cancer (BC) in 2000. This document covered both NMIBC and MIBC. Since these conditions require different treatment strategies, it was decided to give each condition its own guidelines, resulting in the first publication of the MIBC Guidelines in 2004. This 2021 document presents a limited update of the 2020 version.

1.4.2 Summary of changes
New relevant references have been identified through a structured assessment of the literature and incorporated in the various chapters of the 2021 EAU MIBC Guidelines resulting in new sections and added and revised recommendations in:

- Section 3.3.3 Guidelines for the assessment of tumour specimens

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Record the sampling sites, as well as information on tumour size when providing specimens to the pathologist.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

- Section 5.1.8 Summary of evidence and guidelines for the primary assessment of presumably invasive bladder tumours

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In men, prostatic urethral biopsy includes resection from the bladder neck to the verumontanum (between the 5 and 7 o’clock position) using a resection loop. In case any abnormal-looking areas in the prostatic urethra are present at this time, these need to be biopsied as well.</td>
<td>2b</td>
</tr>
</tbody>
</table>
In men with a negative prostatic urethral biopsy undergoing subsequent orthotopic neobladder construction, an intra-operative frozen section can be omitted. (Strong)

In men with a prior positive transurethral prostatic biopsy, subsequent orthotopic neobladder construction should not be denied a priori, unless an intra-operative frozen section of the distal urethral stump reveals malignancy at the level of urethral dissection. (Strong)

- **Section 5.2.1 - Local staging of MIBC; inclusion of data on multiparametric MRI using the Vesical Imaging Reporting and Data System (VI-RADS) scoring system. No new recommendation has been provided.**

- **Section 5.3 - MIBC and health status; this section has been updated, introducing the concept of frailty.**

- **Chapter 6 - Markers; this chapter has been significantly revised, presenting two new recommendations.**

### 6.5 Summary of evidence and recommendations for urothelial markers

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is insufficient evidence to use TMB, molecular subtypes, immune or other gene expression signatures for the management of patients with urothelial cancer.</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate PD-L1 expression (by immunohistochemistry) to determine the potential for use of pembrolizumab or atezolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who are unfit for cisplatin-based chemotherapy.</td>
<td>Weak</td>
</tr>
<tr>
<td>Evaluate for FGFR2/3 genetic alterations for the potential use of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma who have progressed following platinum-containing chemotherapy (including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy).</td>
<td>Weak</td>
</tr>
</tbody>
</table>

- **7.2 - Pre- and post-operative radiotherapy in muscle-invasive bladder cancer; this section was revised and new data added, resulting in an additional recommendation.**

#### 7.2.3 Summary of evidence and guidelines for pre- and post-operative radiotherapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addition of adjuvant RT to chemotherapy is associated with an improvement in local relapse-free survival following cystectomy for locally advanced bladder cancer (pT3b 4, or node-positive).</td>
<td>2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider offering adjuvant radiation in addition to chemotherapy following radical cystectomy, based on pathologic risk (pT3b–4, or positive nodes, or positive margins).</td>
<td>Weak</td>
</tr>
</tbody>
</table>

- **7.3.10 Summary of evidence and guidelines for radical cystectomy and urinary diversion**

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensuring that patients are well informed about the various urinary diversion options prior to making a decision may help prevent or reduce decision regret, independent of the method of diversion selected.</td>
<td>3</td>
</tr>
</tbody>
</table>

- **7.5.4 Trimodality bladder-preserving treatment**

- **7.7 Metastatic disease: data from a number of key trials has been included, in particular on immunotherapy combinations in first- and later-line setting, resulting in a number of new recommendations and a change to the treatment flowchart (Figure 7.2).**
### Summary of evidence and guidelines for metastatic disease

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-1 inhibitor pembrolizumab has been approved for patients that have progressed during or after previous platinum-based chemotherapy based on the results of a phase III trial.</td>
<td>1b</td>
</tr>
<tr>
<td>PD-L1 inhibitors atezolizumab, nivolumab, durvalumab and avelumab have been FDA approved for patients that have progressed during or after previous platinum-based chemotherapy based on the results of a phase II trial.</td>
<td>2a</td>
</tr>
<tr>
<td>PD-1 inhibitor pembrolizumab and PD-L1 inhibitor atezolizumab have been approved for patients with advanced or metastatic UC unfit for cisplatinum-based first-line chemotherapy and with overexpression of PD-L1 based on the results of single-arm phase II trials.</td>
<td>2a</td>
</tr>
<tr>
<td>The combination of chemotherapy plus pembrolizumab or atezolizumab and the combination of durvalumab and tremelimumab have not demonstrated an OS survival benefit compared to platinum-based chemotherapy alone.</td>
<td>1b</td>
</tr>
<tr>
<td>Switch maintenance with the PD-L1 inhibitor avelumab has demonstrated significant OS benefit in patients achieving at least stable disease on first-line platinum-based chemotherapy.</td>
<td>1b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line treatment for platinum-fit patients</strong></td>
<td></td>
</tr>
<tr>
<td>Use cisplatin-containing combination chemotherapy with GC or HD-MVAC.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients unfit for cisplatin but fit for carboplatin use the combination of carboplatin and gemcitabine.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients achieving stable disease, or better, after first-line platinum-based chemotherapy use maintenance treatment with PD-L1 inhibitor avelumab.</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>First-line treatment in patients unfit for platinum-based chemotherapy</strong></td>
<td>Weak</td>
</tr>
<tr>
<td>Consider checkpoint inhibitors pembrolizumab or atezolizumab.</td>
<td></td>
</tr>
<tr>
<td><strong>Second-line treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Offer checkpoint inhibitor pembrolizumab to patients progressing during, or after, platinum-based combination chemotherapy for metastatic disease. If this is not possible, offer atezolizumab, nivolumab (EMA, FDA approved); avelumab or durvalumab (FDA approved).</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>Further treatment after platinum- and immunotherapy</strong></td>
<td></td>
</tr>
<tr>
<td>Offer treatment in clinical trials testing novel antibody drug conjugates (enfortumab vedotin, sacituzumab govitecan); or in case of patients with FGFR3 alterations, FGFR tyrosine kinase inhibitors.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

GC = gemcitabine plus cisplatin; FGFR = fibroblast growth factor receptor; HD-MVAC = high-dose intensity methotrexate, vinblastine, adriamycin plus cisplatin.
2. METHODS

2.1 Data identification

For the 2021 MIBC Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature. A broad and comprehensive literature search, covering all sections of the MIBC Guideline was performed. The search was limited to English language publications. Databases searched included Medline, EMBASE and the Cochrane Libraries, covering a time frame between May 10th, 2019 and May 14th, 2020. A total of 1,837 unique records were identified, retrieved and screened for relevance resulting in 83 new publications having been included in the 2021 print. A detailed search strategy is available online: http://uroweb.org/guideline/bladdercancer-muscle-invasive-andmetastatic/?type=appendices-publications.
For each recommendation within the guidelines there is an accompanying online strength rating form, the basis of which is a modified GRADE methodology [5, 6] which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are grade according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [7];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words ‘strong’ or ‘weak’ [6]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; http://www.uroweb.org/guideline/. A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.

The results of a collaborative multi-stakeholder consensus project on the management of advanced and variant bladder cancer have been incorporated in the 2020 MIBC Guidelines update [8, 9]. Only statements which reached the a priori defined level of agreement - ≥ 70% agreement and ≤ 15% disagreement - across all stakeholders involved in this consensus project are listed. The methodology is presented in detail in the scientific publications. Since the publication of these consensus papers, emerging evidence prompted a re-evaluation of these findings, resulting in the removal of a number of consensus statements.

2.2 Peer-review
The 2021 print of the MIBC guidelines was peer reviewed prior to publication.

2.2.1 Lay review
Post publication, the 2018 MIBC Guidelines were shared with seven patients treated for MIBC. Their comments were requested, but not limited to:

- the overall tone of the guidelines content;
- any missing information;
- any information considered incorrect;
- any information which is not presented in a clear fashion;
- any text which is considered redundant and should be omitted;
- any text section that should be more detailed.

Common comments across reviewers:

- In general, the overall tone of the text was considered informational and instructive, but the language used obviously targets medical professionals, which make certain parts of the text difficult to understand for lay persons. The use of many abbreviations is considered an additional hindrance, as are the methodological elements. In case the EAU are considering producing a lay version of this text, the language needs to be adapted and clear instructions are to be provided.
- It is difficult for lay reviewers to comment on what may be omitted since, in their opinion, they lack the expertise.
- Some sections, such as ‘Recurrent disease’ and ‘Markers’ denote areas where less evidence is available. Consequently, the available data is less systematically presented which makes these sections more difficult to understand.
- There is an interest whether screening for BC is a consideration.
- In particular ‘follow-up’, ‘quality of life’ and ‘survivorship aspects’ should be elaborated on; providing additional information on what may be expected after treatment is considered very helpful for patients and their families. Also lifestyle elements would be of relevance (healthy living, “what to do to prevent cancer”). For this section, in particular, involvement of patients in the text development was considered missing. Transparency about the process of patient involvement in guidelines development was considered most relevant.

The MIBC Guidelines Panel is most grateful for the unique insights and guidance provided by the lay reviewers.
2.3 Future goals
The MIBC Panel will integrate two patient advocates in the course of 2021, to ensure that patient views will be appropriately represented in the course of the production of these guidelines.

Topics considered for inclusion in the 2022 update of the MIBC Guidelines:
- development of a diagnostic pathway for the assessment of visible and non-visible haematuria;
- participation in developing strategies to ensure meaningful participation of patients in the development and implementation of the MIBC Guidelines.

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology
Bladder cancer is the 7th most commonly diagnosed cancer in males, whilst it drops to 10th position when both genders are considered [10]. The worldwide age-standardised incidence rate (per 100,000 person/years) is 9.5 for men and 2.4 for women [10]. In the European Union, the age-standardised incidence rate is 20 for men and 4.6 for women [10]. In Europe, the highest age-standardised incidence rate has been reported in Belgium (31 in men and 6.2 in women) and the lowest in Finland (18.1 in men and 4.3 in women) [10].

Worldwide, the BC age-standardised mortality rate (per 100,000 person/years) was 3.2 for men vs. 0.9 for women in 2012 [10]. Bladder cancer incidence and mortality rates vary across countries due to differences in risk factors, detection and diagnostic practices, and availability of treatments. The variations are, however, also partly caused by the different methodologies used in the studies and the quality of data collection [11, 12].

The incidence and mortality of BC has decreased in some registries, possibly reflecting the decreased impact of causative agents [12, 13].

Approximately 75% of patients with BC present with disease confined to the mucosa (stage Ta, carcinoma in situ [CIS]) or submucosa (stage T1). In younger patients (< 40 years) this percentage is even higher [14]. Patients with TaT1 and CIS have a high prevalence due to long-term survival in many cases and lower risk of cancer-specific mortality (CSM) compared to T2-4 tumours [10, 11].

3.2 Aetiology

3.2.1 Tobacco smoking
Tobacco smoking is the most well-established risk factor for BC, causing 50–65% of male cases and 20–30% of female cases [15]. A causal relationship has been established between exposure to tobacco and cancer in studies in which chance, bias and confounding can be discounted with reasonable confidence [16].

The incidence of BC is directly related to the duration of smoking and the number of cigarettes smoked per day [17]. A meta-analysis looked at 216 observational studies on cigarette smoking and cancer published between 1961 and 2003, and the pooled risk estimates for BC demonstrated a significant association for both current and former smokers [18]. Recently, an increase in risk estimates for current smokers relative to never smokers has been described suggesting this could be due to changes in cigarette composition [15]. Starting to smoke at a younger age increased the risk of death from BC [19]. An immediate decrease in the risk of BC was observed in those who stopped smoking. The reduction was about 40% within one to four years of quitting smoking and 60% after 25 years of cessation [17]. Encouraging people to stop smoking would result in the incidence of BC decreasing equally in men and women [15].

3.2.2 Occupational exposure to chemicals
Occupational exposure is the second most important risk factor for BC. Work-related cases accounted for 20–25% of all BC cases in several series and it is likely to occur in occupations in which dyes, rubbers, textiles, paints, leathers, and chemicals are used [20]. The risk of BC due to occupational exposure to carcinogenic aromatic amines is significantly greater after ten years or more of exposure; the mean latency period usually exceeds 30 years [21, 22]. Population-based studies established the occupational attribution for BC in men to be 7.1%, while no such attribution was discernible for women [11, 23].

3.2.3 Radiotherapy
Increased rates of secondary bladder malignancies have been reported after external-beam radiotherapy (EBRT) for gynaecological malignancies, with relative risks (RR) of 2–4 [24]. In a population-based cohort study,
the standardised incidence ratios for BC developing after radical prostatectomy (RP), EBRT, brachytherapy, and EBRT-brachytherapy were 0.99, 1.42, 1.10, and 1.39, respectively, in comparison with the general U.S. population [25].

It has recently been proposed that patients who have received radiotherapy (RT) for prostate cancer with modern modalities such as intensity-modulated radiotherapy (IMRT) may have lower rates of in-field bladder- and rectal secondary malignancies [26]. Nevertheless, since longer follow-up data are not yet available, and as BC requires a long period to develop, patients treated with radiation and with a long life expectancy are at a higher risk of developing BC [26].

3.2.4 Dietary factors
Several dietary factors have been related to BC; however, the links remain controversial. The European Prospective Investigation into Cancer and Nutrition (EPIC) study is an on-going multicentre cohort study designed to examine the association between diet, lifestyle, environmental factors and cancer. They found no links between BC and fluid intake, red meat, vegetable and fruit consumption and only recently an inverse association between dietary intake of flavonoids and lignans and the risk of aggressive BC tumours has been described [27].

3.2.5 Metabolic disorders
In a large prospective study pooling six cohorts from Norway, Sweden, and Austria (The Metabolic syndrome and Cancer project, Me-Can 2.0), metabolic aberrations, especially elevated blood pressure and triglycerides, were associated with increased risks of BC among men, whereas high body mass index (BMI) was associated with decreased BC risk. The associations between BMI, blood pressure and BC risk significantly differed between men and women [28].

The association of diabetes mellitus (DM) with the risk of BC has been evaluated in numerous meta-analyses with inconsistent results. When analysing specific subpopulations, DM was associated with BC or CSM risk especially in men [29]. Thiazolidinediones (pioglitazone and rosiglitazone) are oral hypoglycaemic drugs used for the management of type 2 DM. Their use and the association with BC is still a matter of debate. In a recent meta-analysis of observational studies the summary results indicated that pioglitazone use was significantly associated with an increased risk of BC which appears to be linked to higher dose and longer duration of treatment [30]. The U.S. Food and Drug Administration (FDA) recommend that healthcare professionals should not prescribe pioglitazone in patients with active BC. Several countries in Europe have removed this agent from the market or included warnings for prescription. Moreover, the benefits of glycaemic control vs. unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of BC.

3.2.6 Bladder schistosomiasis and chronic urinary tract infection
Bladder schistosomiasis (bilharzia) is the second most common parasitic infection after malaria, with about 600 million people exposed to infection in Africa, Asia, South America, and the Caribbean [31]. There is a well-established relationship between schistosomiasis and urothelial carcinoma (UC) of the bladder, which can progress to squamous cell carcinoma (SCC), however, better control of the disease is decreasing the incidence of SCC of the bladder in endemic zones such as Egypt [32, 33].

Similarly, invasive SCC has been linked to the presence of chronic urinary tract infection (UTI) distinct from schistosomiasis. A direct association between BC and UTIs has been observed in several case-control studies, which have reported a two-fold increased risk of BC in patients with recurrent UTIs in some series [34]. However, a recent meta-analysis found no statistical association when pooling data from the most recent and highest quality studies which highlights the need for higher quality data to be able to draw conclusions [35].

Similarly, urinary calculi and chronic irritation or inflammation of the urothelium have been described as possible risk factors for BC. A meta-analysis of case-control and cohort studies suggests a positive association between history of urinary calculi and BC [36].

3.2.7 Gender
Although men are more likely to develop BC than women, women present with more advanced disease and have worse survival rates. A meta-analysis including nearly 28,000 patients shows that female gender was associated with a worse survival outcome (hazard ratio [HR]: 1.20, 95% CI: 1.09–1.32) compared to male gender after radical cystectomy (RC) [37]. This finding had already been presented in a descriptive nationwide analysis based on 27,773 Austrian patients. After their analysis the authors found that cancer-specific survival (CSS) was identical for pT1-tumours in both sexes, while women had a worse CSS in both age cohorts (< 70 years and ≥ 70 years) with higher tumour stages [38]. However, treatment patterns are unlikely to explain the differences in overall survival (OS) [39]. In a population-based study from the Ontario Cancer Registry analysing all patients with BC treated with cystectomy or radical RT between 1994 and 2008, no differences in
OS, mortality and outcomes were found between males and females following radical therapy [40]. The gender-specific difference in survival for patients with BC was also analysed in the Norwegian population. Survival was inferior for female patients but only within the first 2 years after diagnosis. This discrepancy was partly attributed to a more severe T-stage in female patients at initial diagnoses [41].

A population-based study from the MarketScan databases suggests that a possible reason for worse survival in the female population may be that women experienced longer delays in diagnosis than men, as the differential diagnosis in women includes diseases that are more prevalent than BC [42]. Furthermore, differences in the gender prevalence of BC may be due to other factors besides tobacco and chemical exposure. In a large prospective cohort study, post-menopausal status was associated with an increase in BC risk, even after adjustment for smoking status. This finding suggests that the differences in oestrogen and androgen levels between men and women may be responsible for some of the difference in the gender prevalence of BC [43-45]. Moreover, a recent population study assessing impact of hormones on BC suggests that younger age at menopause (< 45 years) is associated with an increased risk of BC [46].

3.2.8 Genetic factors
There is growing evidence that genetic susceptibility factors and family association may influence the incidence of BC. A recent population-based study of cancer risk in relatives and spouses of UC patients showed an increased risk for first- and second-degree relatives, and suggests genetic or environmental roots independent of smoking-related behaviour [47]. Shared environmental exposure was recognised as a potentially confounding factor [48]. Recent studies detected genetic susceptibility with independent loci, which are associated with BC risk [49].

Genome-wide association studies (GWAS) of BC identified several susceptibility loci associated with BC risk [50, 51].

3.2.9 Summary of evidence and guidelines for epidemiology and risk factors

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worldwide, bladder cancer is the 10th most commonly diagnosed cancer.</td>
<td>2a</td>
</tr>
<tr>
<td>Several risk factors associated with bladder cancer diagnosis have been identified.</td>
<td>3</td>
</tr>
<tr>
<td>Active and passive tobacco smoking continues to be the main risk factor, while exposure-related incidence is decreasing.</td>
<td>2a</td>
</tr>
<tr>
<td>The increased risk of developing bladder cancer in patients undergoing external-beam radiotherapy (EBRT), brachytherapy, or a combination of EBRT and brachytherapy, must be considered during patient follow-up. As bladder cancer requires time to develop, patients treated with radiation at a young age are at the greatest risk and should be followed-up closely.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Council patients to stop active and avoid passive smoking.</td>
<td>Strong</td>
</tr>
<tr>
<td>Inform workers in potentially hazardous workplaces of the potential carcinogenic effects of a number of recognised substances, including duration of exposure and latency periods. Protective measures are recommended.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not prescribe pioglitazone to patients with active bladder cancer or a history of bladder cancer.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

3.3 Pathology

3.3.1 Handling of transurethral resection and cystectomy specimens
During transurethral resection (TUR), a specimen from the tumour and normal looking bladder wall should be taken, if possible. Specimens should be taken from the superficial and deep areas of the tumour and sent to the pathology laboratory separately, in case the outcome will impact on treatment decisions. If random biopsies of the flat mucosa are taken, each biopsy specimen of the flat mucosa should also be submitted separately [52]. The sampling sites must be recorded by the urologist; the pathologist report should include location of tumour tissue in the cystectomy specimen. Anatomical tumour location is relevant for staging and prognosis [53, 54].

In RC, bladder fixation must be carried out as soon as possible. The pathologist must open the specimen from the urethra to the bladder dome and fix the specimen. In a female cystectomy specimen, the length of the urethral segment removed en bloc with the specimen should be checked, preferably by the urological surgeon [55].
Specimen handling should follow the general rules as published by a collaborative group of pathologists and urologists [56, 57]. It must be stressed that it may be very difficult to confirm the presence of a neoplastic lesion using gross examination of the cystectomy specimen after TUR or chemotherapy, so the entire retracted or ulcerated area should be included.

It is compulsory to study the urethra, the ureters, the prostate in men and the radial margins [58]. In urethra-sparing cystectomy; the level of urethral dissection, completeness of the prostate, specifically at the apex (in men), and the inclusion of the entire bladder neck and amount of adjacent urethra, uterus and vaginal vault (in women) have to be documented by the pathologist.

All lymph node (LN) specimens should be provided in their totality, in clearly labelled containers. In case of doubt, or adipose differentiation of the LNs, the entire specimen is to be included. Lymph nodes should be counted and measured on slides; capsular extension and percentage of LN invasion should be reported as well as vascular embols [59, 60]. In case of metastatic spread in the perivesical fat without real LN structures (capsule, subcapsular sinus), this localisation should nevertheless be considered as N+.

Potentially positive soft tissue margins should be inked by the pathologist for evaluation [61]. In rare cases, fresh frozen sections may be helpful to determine treatment strategy [62].

3.3.2 Pathology of muscle-invasive bladder cancer
All MIBC cases are high-grade UCs. For this reason, no prognostic information can be provided by grading MIBC [63]. However, identification of morphological subtypes is important for prognostic reasons and treatment decisions [64-66].

The data presented in these guidelines are based on the 2004/2016 World Health Organization (WHO) classifications [67, 68].

Currently the following differentiations are used [64, 69]:
1. urothelial carcinoma (more than 90% of all cases);
2. urothelial carcinomas with partial squamous and/or glandular or trophoblastic differentiation;
3. micropapillary urothelial carcinoma;
4. nested variant (including large nested variant) and microcystic urothelial carcinoma;
5. plasmacytoid, giant cell, signet ring, diffuse, undifferentiated;
6. lymphoepithelioma-like;
7. small-cell carcinomas;
8. sarcomatoid urothelial carcinomas;
9. neuroendocrine variant of urothelial carcinoma;
10. some urothelial carcinomas with other rare differentiations.

Outcomes may vary for divergent histologies, which need to be mentioned following international reporting standards [64, 70].

3.3.3 Guidelines for the assessment of tumour specimens

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Record the depth of invasion (categories pT2a and pT2b, pT3a and pT3b or pT4a and pT4b).</td>
<td>Strong</td>
</tr>
<tr>
<td>Record margins with special attention paid to the radial margin, prostate, ureter, urethra, peritoneal fat, uterus and vaginal vault.</td>
<td></td>
</tr>
<tr>
<td>Record the total number of lymph nodes (LNs), the number of positive LNs and extranodal spread.</td>
<td></td>
</tr>
<tr>
<td>Record lymphatic or blood vessel invasion.</td>
<td></td>
</tr>
<tr>
<td>Record the presence of carcinoma in situ.</td>
<td></td>
</tr>
<tr>
<td>Record the sampling sites as well as information on tumour size when providing specimens to the pathologist.</td>
<td></td>
</tr>
</tbody>
</table>
3.3.4 **EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer** [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder urothelial carcinoma with small cell neuroendocrine variant should be treated with neoadjuvant chemotherapy followed by consolidating local therapy.</td>
</tr>
<tr>
<td>Muscle-invasive pure squamous cell carcinoma of the bladder should be treated with primary radical cystectomy and lymphadenectomy.</td>
</tr>
<tr>
<td>Muscle-invasive pure adenocarcinoma of the bladder should be treated with primary radical cystectomy and lymphadenectomy.</td>
</tr>
<tr>
<td>Muscle-invasive small cell neuroendocrine variant of bladder urothelial carcinoma should not receive preventive brain irradiation to avoid brain recurrence.</td>
</tr>
<tr>
<td>Differentiating between urachal and non-urachal subtypes of adenocarcinoma is essential when making treatment decisions.</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

### 4. STAGING AND CLASSIFICATION SYSTEMS

#### 4.1 Pathological staging
For staging, the Tumour, Node, Metastasis (TNM) Classification (2017, 8th edition) is recommended [71]. Blood and lymphatic vessel invasion have an independent prognostic significance [72, 73].

#### 4.2 Tumour, node, metastasis classification
The TNM classification of malignant tumours is the method most widely used to classify the extent of cancer spread [71] (Table 4.1).

**Table 4.1: TNM Classification of urinary bladder cancer** [71]

<table>
<thead>
<tr>
<th>T - Primary Tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tx</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Ta</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>T2</td>
</tr>
<tr>
<td>T2a</td>
</tr>
<tr>
<td>T2b</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T3a</td>
</tr>
<tr>
<td>T3b</td>
</tr>
<tr>
<td>T4</td>
</tr>
<tr>
<td>T4a</td>
</tr>
<tr>
<td>T4b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N - Regional Lymph Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nx</td>
</tr>
<tr>
<td>N0</td>
</tr>
<tr>
<td>N1</td>
</tr>
<tr>
<td>N2</td>
</tr>
<tr>
<td>N3</td>
</tr>
</tbody>
</table>
### M - Distant Metastasis

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Non-regional lymph nodes</td>
</tr>
<tr>
<td>M1b</td>
<td>Other distant metastasis</td>
</tr>
</tbody>
</table>

Staging after neo-adjuvant chemotherapy (NAC) and radical cystectomy can be done, but must be mentioned as ypTNM (International Collaboration on Cancer Reporting) [70]. ypT0N0 after NAC and cystectomy is associated with good prognosis [74, 75].

# 5. DIAGNOSTIC EVALUATION

## 5.1 Primary diagnosis

### 5.1.1 Symptoms

Painless visible haematuria is the most common presenting complaint. Other presenting symptoms and clinical signs include non-visible haematuria, urgency, dysuria, increased frequency, and in more advanced tumours, pelvic pain and symptoms related to urinary tract obstruction.

### 5.1.2 Physical examination

Physical examination should include rectal and vaginal bimanual palpation. A palpable pelvic mass can be found in patients with locally advanced tumours. In addition, bimanual examination under anaesthesia should be carried out before and after TUR of the bladder (TURB) to assess whether there is a palpable mass or if the tumour is fixed to the pelvic wall [76, 77]. However, considering the discrepancy between bimanual examination and pT stage after cystectomy (11% clinical overstaging and 31% clinical understaging), some caution is suggested with the interpretation of bimanual examination [78].

### 5.1.3 Bladder imaging

Patients with a bladder mass identified by any diagnostic imaging technique should undergo cystoscopy, biopsy and/or resection for histopathological diagnosis and staging.

The high specificity of diagnostic imaging for detecting bladder cancer means that patients with imaging positive for bladder cancer may avoid diagnostic flexible cystoscopy and go directly to rigid cystoscopy and transurethral resection [79, 80].

### 5.1.4 Urinary cytology

Examination of voided urine or bladder washings for exfoliated cancer cells has high sensitivity in high-grade tumours and is a useful indicator in cases of high-grade malignancy or CIS. However, positive urinary cytology may originate from a urothelial tumour located anywhere in the urinary tract.

Evaluation of cytology specimens can be hampered by low cellular yield, UTIs, stones or intravesical instillations, but for experienced readers, specificity exceeds 90% [81, 82]. However, negative cytology does not exclude a tumour. There is no known urinary marker specific for the diagnosis of invasive BC [83].

A standardised reporting system, the ‘Paris System’ redefining urinary cytology diagnostic categories was published in 2016 [84]:

- adequacy of urine specimens (Adequacy);
- negative for high-grade UC (Negative);
- atypical urothelial cells (AUC);
- suspicious for high-grade UC (Suspicious);
- high-grade UC (HGUC);
- low-grade urothelial neoplasia (LGUN).

### 5.1.5 Cystoscopy

Ultimately, the diagnosis of BC is made by cystoscopy and histological evaluation of resected tissue. An (outpatient) flexible cystoscopy is recommended to obtain a complete image of the bladder. However, in daily practice, if a bladder tumour has been visualised unequivocally by imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound (US), diagnostic cystoscopy may be omitted and the patient can proceed directly to TURB for histological diagnosis and resection. During the procedure, a thorough investigation of the bladder with rigid cystoscopy under anaesthesia is mandatory in order not to miss any tumours at the level of the bladder neck.
Currently, there is no evidence for the role of photodynamic diagnosis (PDD) in the standard diagnosis of invasive BC.

A careful description of the cystoscopic findings is necessary. This should include documentation of the site, size, number, and appearance (papillary or solid) of the tumours, as well as a description of any mucosal abnormalities [85]. The use of a bladder diagram is recommended.

The use of PDD could be considered if a T1 high-grade tumour is present and to identify associated CIS. Presence of CIS may lead to a modified treatment plan (see EAU Guidelines on Non-muscle-invasive Bladder Cancer [2]). Photodynamic diagnosis is highly sensitive for the detection of CIS and in experienced hands the rate of false-positive results may be similar to that with regular white-light cystoscopy [73, 86].

5.1.6 Transurethral resection of invasive bladder tumours
The goal of TURB is to enable histopathological diagnosis and staging, which requires the inclusion of bladder muscle in the resection specimen.

In case MIBC is suspected, tumours need to be resected separately in parts, which include the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle, and the edges of the resection area. At least the deeper part of the resection specimen must be referred to the pathologist in a separate labelled container to enable making a correct diagnosis. In cases in which RT is considered and CIS is to be excluded, PDD can be used [87].

The involvement of the prostatic urethra and ducts in men with bladder tumours has been reported. The exact risk is not known, but it seems to be higher if the tumour is located on the trigone or bladder neck, with concomitant bladder CIS, and in the case of multiple tumours [54, 88, 89]. Involvement of the prostatic urethra can be determined either at the time of primary TURB or by frozen section during the cystoprostatectomy procedure. A frozen section has a higher negative-predictive value and is more accurate [90-92].

A negative urethral frozen section can reliably identify patients in whom urethrectomy should be avoided. However, a positive pre-operative biopsy seems to have limited utility as these findings are not reliably associated with final margin status [90, 93].

Diagnosis of a urethral tumour before cystectomy will result in a urethrectomy which could be a contraindication for an orthotopic diversion. However, an orthotopic diversion should not be denied based on positive pre-operative biopsy findings alone and frozen section should be part of the radical cystectomy procedure, in particular in male patients [94, 95].

5.1.7 Concomitant prostate cancer
Prostate cancer is found in 21–50% of male patients undergoing RC for BC [96-99]. Incidentally discovered clinically significant prostatic adenocarcinoma did not alter survival [98, 99]. Pathological reporting of the specimens should follow the recommendations as presented in the EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer [100].

5.1.8 Summary of evidence and guidelines for the primary assessment of presumably invasive bladder tumours

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystoscopy is necessary for the diagnosis of bladder cancer.</td>
<td>1</td>
</tr>
<tr>
<td>Urinary cytology has high sensitivity in high-grade tumours including carcinoma in situ.</td>
<td>2b</td>
</tr>
<tr>
<td>In men, prostatic urethral biopsy includes resection from the bladder neck to the verumontanum (between the 5 and 7 o’clock position) using a resection loop. In case any abnormal-looking areas in the prostatic urethra are present at this time, these need to be biopsied as well.</td>
<td>2b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities during cystoscopy. Use a bladder diagram.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take a biopsy of the prostatic urethra in cases of bladder neck tumour, when bladder carcinoma in situ is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible.</td>
<td>Strong</td>
</tr>
<tr>
<td>In men with a negative prostatic urethral biopsy undergoing subsequent orthotopic neobladder construction an intra-operative frozen section can be omitted.</td>
<td>Strong</td>
</tr>
</tbody>
</table>
In men with a prior positive transurethral prostatic biopsy, subsequent orthotopic neobladder construction should not be denied a priori, unless an intra-operative frozen section of the distal urethral stump reveals malignancy at the level of urethral dissection. **Strong**

In women undergoing subsequent orthotopic neobladder construction, obtain procedural information (including histological evaluation) of the bladder neck and urethral margin, either prior to, or at the time of cystectomy. **Strong**

In the pathology report, specify the grade, depth of tumour invasion, and whether the lamina propria and muscle tissue are present in the specimen. **Strong**

(For general information on the assessment of bladder tumours, see EAU Guidelines on Non-muscle-invasive Bladder Cancer [2]).

### Consensus statement

Differentiating between urachal and non-urachal subtypes of adenocarcinoma is essential when making treatment decisions.

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).*

#### 5.2 Imaging for staging of MIBC

In clinical practice, tumour stage and histopathological grade are used to guide treatment and determine prognosis [69, 101, 102]. Computed tomography and MRI are the imaging techniques most commonly used for tumour staging. If the correct choice of treatment is to be made, staging must be accurate.

The goal of imaging patients with bladder cancer is to determine:

- extent of local tumour invasion, ideally differentiating T1 from T2 tumours as the treatment is different;
- tumour spread to LNs;
- tumour spread to the upper UT and other distant organs (e.g., liver, lungs, bones, peritoneum, pleura, and adrenal glands).

**5.2.1 Local staging of MIBC**

Multiparametric MRI (mpMRI) using the Vesical Imaging Reporting and Data System (VI-RADS) scoring system may differentiate between muscle- and non-muscle-invasive primary BC with high diagnostic accuracy. A recent meta-analysis found that the pooled sensitivity and specificity of mpMRI with VI-RADS acquisition and scoring for predicting MIBC were 0.83 and 0.90, respectively. This diagnostic performance of VI-RADS is similar to the diagnostic performance of bladder MRI in determining MIBC prior to the introduction of VI-RADS based on a previous meta-analysis of 24 studies in which the pooled sensitivity and specificity were 0.92 (95% CI: 0.88–0.95) and 0.87 (95% CI: 0.78–0.93), respectively [103]. The Vesical Imaging Reporting and Data System offers a standardised approach to both acquisition and reporting of mpMRI for BC. How mpMRI is best used in clinical practice and which cut off levels to use for VI-RADS scoring is still to be determined [103].

Magnetic resonance imaging has superior soft tissue contrast resolution compared with CT. The accuracy of MRI for primary tumour staging varies from 73% to 96% (mean 85%). A meta-analysis of 17 studies showed a 91% sensitivity and 96% specificity for 3.0-T device MRI combined with diffusion-weighted imaging (DWI) to differentiate ≤T1 tumours from ≥ T2 tumours before surgery [104].

Both CT and MRI may be used for assessment of local invasion by T3b disease, or higher, but they are unable to accurately diagnose microscopic invasion of perivesical fat (T2 vs. T3a) [105].

Magnetic resonance imaging may evaluate post-biopsy reaction because enhancement of the tumour occurs earlier than that of the normal bladder wall due to neovascularisation [106, 107].

In 2006, a link was established between the use of gadolinium-based contrast agents and nephrogenic systemic fibrosis (NSF), which may result in fatal or severely debilitating systemic fibrosis. Patients with impaired renal function are at risk of developing NSF and non-ionic linear gadolinium-based contrast agents should be avoided (gadodiamide, gadopentetate dimeglumine and gadoversetamide). A stable macrocyclic contrast agent should be used (gadobutrol, gadoterate meglumine or gadoteridol). Contrast-enhanced CT using iodinated contrast media can be considered as an alternative [108].
5.2.1 CT imaging for local staging of MIBC

The advantages of CT include high spatial resolution, shorter acquisition time, wider coverage in a single breath hold, and lower susceptibility to variable patient factors. Computed tomography is unable to differentiate between stages Ta to T3a tumours, but it is useful for detecting invasion into the perivesical fat (T3b) and adjacent organs. The accuracy of CT in determining extravesical tumour extension varies from 55% to 92% and increases with more advanced disease.

5.2.2 Imaging of lymph nodes in MIBC

Assessment of LN metastases based solely on size is limited by the inability of both CT and MRI to identify metastases in normal-sized or minimally-enlarged nodes. The sensitivity for detection of LN metastases is low (48–87%). Specificity is also low because nodal enlargement may be due to benign disease. Overall, CT and MRI show similar results in the detection of LN metastases in a variety of primary pelvic tumours. Pelvic nodes > 8 mm and abdominal nodes > 10 mm in maximum short-axis diameter, detected by CT or MRI, should be regarded as pathologically enlarged.

Positron emission tomography (PET) combined with CT is increasingly being used in clinical practice and its exact role continues to be evaluated.

5.2.3 Upper urinary tract urothelial carcinoma

5.2.3.1 Computed tomography urography

Computed tomography urography has the highest diagnostic accuracy of the available imaging techniques. The sensitivity of CT urography for UTUC is 0.67–1.0 and specificity is 0.93–0.99.

Rapid acquisition of thin sections allows high-resolution isotropic images that can be viewed in multiple planes to assist with diagnosis without loss of resolution. Epithelial “flat lesions” without mass effect or urothelial thickening are generally not visible with CT.

The secondary sign of hydronephrosis is associated with advanced disease and poor oncological outcome. The presence of enlarged LNs is highly predictive of metastases in UTUC.

5.2.3.2 Magnetic resonance urography

Magnetic resonance urography is indicated in patients who cannot undergo CT urography, usually when radiation or iodinated contrast media are contraindicated. The sensitivity of MR urography is 0.75 after contrast injection for tumours < 2 cm. The use of MR urography with gadolinium-based contrast media should be limited in patients with severe renal impairment (< 30 mL/min creatinine clearance), due to the risk of NSF. Computed tomography urography is generally preferred to MR urography for diagnosing and staging UTUC.

5.2.4 Distant metastases at sites other than lymph nodes

Prior to any curative treatment, it is essential to evaluate the presence of distant metastases. Computed tomography and MRI are the diagnostic techniques of choice to detect lung and liver metastases, respectively. Bone and brain metastases are rare at the time of presentation of invasive BC. A bone scan and additional brain imaging are therefore not routinely indicated unless the patient has specific symptoms or signs to suggest bone or brain metastases. Magnetic resonance imaging is more sensitive and specific for diagnosing bone metastases than bone scintigraphy.

5.2.5 Future developments

Evidence is accruing in the literature suggesting that 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT might have potential clinical use for staging metastatic BC, but there is no consensus as yet. The results of further trials are awaited before a recommendation can be made. Recently, the first study was published showing the superior feasibility of DWI over T2-weighted and dynamic contrast-enhanced (DCE)-MRI in assessing the therapeutic response to induction chemotherapy against MIBC.

The high specificity of DWI indicates that it is useful for accurate prediction of a complete histopathological response, allowing better patient selection for bladder-sparing protocols. Results from prospective studies are awaited.
Summary of evidence and guidelines for staging in muscle-invasive bladder cancer

5.2.6 Summary of evidence and guidelines for staging in muscle-invasive bladder cancer (MIBC) provides information about prognosis and assists in selection of the most appropriate treatment.

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging as part of staging in muscle-invasive bladder cancer (MIBC) provides information about prognosis and assists in selection of the most appropriate treatment.</td>
<td>2b</td>
</tr>
<tr>
<td>There are currently insufficient data on the use of diffusion-weighted imaging (DWI) and $^{18}$F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in MIBC to allow for a recommendation to be made.</td>
<td>2</td>
</tr>
<tr>
<td>The diagnosis of upper tract urothelial carcinoma depends on CT urography and ureteroscopy.</td>
<td>2</td>
</tr>
</tbody>
</table>

**Recommendations**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with confirmed muscle-invasive bladder cancer, use computed tomography (CT) of the chest, abdomen and pelvis for staging, including some form of CT urography with designated phases for optimal urothelial evaluation.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use magnetic resonance urography when CT urography is contraindicated for reasons related to contrast administration or radiation dose.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use CT or magnetic resonance imaging (MRI) for staging locally advanced or metastatic disease in patients in whom radical treatment is considered.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use CT to diagnose pulmonary metastases. Computed tomography and MRI are generally equivalent for diagnosing local disease and distant metastases in the abdomen.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

5.3 MIBC and health status

Complications from RC may be directly related to pre-existing comorbidity as well as the surgical procedure, bowel anastomosis, or urinary diversion. A significant body of literature has evaluated the usefulness of age as a prognostic factor for RC, although chronological age is less important than frailty [134-136]. Frailty is a syndrome of reduced ability to respond to stressors. Patients with frailty have a higher risk of mortality and negative side effects of cancer treatment [137]. Controversy remains regarding age, RC and the type of urinary diversion. Radical cystectomy is associated with the greatest risk reduction in disease-related and non-disease-related death in patients aged < 80 years [138].

The largest retrospective study on RC in septuagenarians and octogenarians based on data from the National Surgical Quality Improvement Program database ($n = 1,710$) showed no significant difference for wound, cardiac, or pulmonary complications. However, the risk of mortality in octogenarians compared to septuagenarians is higher (4.3% vs. 2.3%) [139]. Although some octogenarians successfully underwent a neobladder procedure, most patients were treated with an ileal conduit diversion. It is important to evaluate functioning and quality of life (QoL) of older patients using a standardised geriatric assessment, as well as carrying out a standard medical evaluation [140].

Sarcopenia has been shown to be an independent predictor for OS and CSS in a large multicentre study with patients undergoing RC for BC [141]. In order to predict CSM after RC in patients receiving neoadjuvant chemotherapy (NAC), sarcopenia should be assessed after completing the chemotherapy [142]. Other risk factors for morbidity include prior abdominal surgery, extravesical disease, and prior RT [143]. Female gender, an increased BMI and lower pre-operative albumin levels are associated with a higher rate of parastomal hernias [144]. Low pre-operative serum albumin is also associated with impaired wound healing, gastrointestinal (GI) complications and a decrease of recurrence-free and OS after RC [145, 146]. Therefore, it could be used as a prognostic biomarker for patients undergoing RC.

5.3.1 Evaluation of comorbidity, frailty and cognition

Rochon et al. have shown that evaluation of comorbidity provides a better indicator of life expectancy in MIBC than patient age [147]. Evaluation of comorbidity helps to identify factors likely to interfere with, or have an impact on, treatment and the evolution and prognosis of MIBC [148].

The value of assessing overall health before recommending and proceeding with surgery was emphasised by Zietman et al., who have demonstrated an association between comorbidity and adverse pathological and survival outcomes following RC [149]. Similar results were found for the impact of comorbidity on cancer-specific and other-cause mortality in a population-based competing risk analysis of > 11,260 patients from the Surveillance, Epidemiology, and End Results (SEER) registries. Age carried the highest risk for other-cause mortality but not for increased cancer-specific death, while the stage of locally advanced tumour was the strongest predictor for decreased CSS [150].

Stratifying older patients according to frailty using a multidisciplinary approach will help select
patients most likely to benefit from radical surgery and to optimise treatment outcomes [151]. There are many different screening tools available for frailty and local approaches can be used. Examples include the G8 and the Clinical Frailty Scale (See Table 5.1 and Figure 5.1 below).

Cognitive impairment can be screened for using a tool such as the mini-COG (https://mini-cog.com), which consists of three-word recall and a clock-drawing test, and can be completed within 5 minutes. A score of ≤ 3/5 indicates the need to refer the patient for full cognitive assessment. Patients with any form of cognitive impairment (e.g., Alzheimer’s or vascular dementia) may need a capacity assessment of their ability to make an informed decision, which is an important factor in health status assessment. Cognitive impairment also predicts risk of delirium, which is important for patients undergoing surgery [152].

Table 5.1: G8 screening tool (adapted from [153])

<table>
<thead>
<tr>
<th>Items</th>
<th>Possible responses (score)</th>
</tr>
</thead>
</table>
| **A** Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties? | 0 = severe decrease in food intake  
1 = moderate decrease in food intake  
2 = no decrease in food intake |
| **B** Weight loss during the last 3 months?                          | 0 = weight loss > 3 kg  
1 = does not know  
2 = weight loss between 1 and 3 kg  
3 = no weight loss |
| **C** Mobility?                                                       | 0 = bed or chair bound  
1 = able to get out of bed/chair but does not go out  
2 = goes out |
| **D** Neuropsychological problems?                                    | 0 = severe dementia or depression  
1 = mild dementia  
2 = no psychological problems |
| **E** BMI? (weight in kg)/(height in m²)                              | 0 = BMI < 19  
1 = BMI 19 to < 21  
2 = BMI 21 to < 23  
3 = BMI ≥ 23 |
| **F** Takes more than three prescription drugs per day?              | 0 = yes  
1 = no |
| **G** In comparison with other people of the same age, how does the patient consider his/her health status? | 0.0 = not as good  
0.5 = does not know  
1.0 = as good  
2.0 = better |
| **H** Age                                                             | 0 = ≥ 85  
1 = 80–85  
2 = < 80 |
| **Total score**                                                       | 0–17 |
Patients with advanced BC have often problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.

In BC, the CGA has been used to adapt gemcitabine chemotherapy in previously untreated older patients [177]. In BC, the CGA has been used to adapt gemcitabine chemotherapy in previously untreated older patients with advanced BC [178].

**CLINICAL FRAILTY SCALE**

1. **VERY FIT**
   - People who are robust, active, energetic and motivated. They tend to exercise regularly and are among the fittest for their age.

2. **FIT**
   - People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g., seasonally.

3. **MANAGING WELL**
   - People whose medical problems are well controlled, even if occasionally symptomatic, but often are not regularly active beyond routine walking.

4. **LIVING WITH VERY MILD FRAILTY**
   - Previously “vulnerable” this category marks early transition from complete independence. While not dependent on others for daily help, often symptoms limit activities. A common complaint is being “slowed up” and/or being tired during the day.

5. **LIVING WITH MILD FRAILTY**
   - People who often have more evident slowing, and need help with high order instrumental activities of daily living (finances, transportation, heavy housework). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation, medications and begins to restrict light housework.

6. **LIVING WITH MODERATE FRAILTY**
   - People who need help with all outside activities and with keeping house.

7. **LIVING WITH SEVERE FRAILTY**
   - Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within – 6 months).

8. **LIVING WITH VERY SEVERE FRAILTY**
   - Completely dependent for personal care and approaching end of life. Typically, they could not recover even from a minor illness.

9. **TERMINALLY ILL**
   - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise living with severe frailty. (Many terminally ill people can still exercise until very close to death.)

**SCORING FRAILTY IN PEOPLE WITH DEMENTIA**

The degree of frailty generally corresponds to the degree of dementia. Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

In very severe dementia they are often bedfast. Many are virtually mute.

**Clinical Frailty Scale ©2005–2020 Rockwood, Version 2.0 (EN). All rights reserved. For permission:**

www.geriatricmedicineresearch.ca


*Permission to reproduce the Clinical Frailty Scale© has been granted by the copyright holder.

5.3.2 **Comorbidity scales, anaesthetic risk classification and geriatric assessment**

A range of comorbidity scales has been developed [155], seven of which have been validated [156-162]. The Charlson Comorbidity Index (CCI) ranges from 0 to 30 according to the importance of comorbidity described at four levels and is calculated by healthcare practitioners based on patients’ medical records. The score has been widely studied in patients with BC and found to be an independent prognostic factor for peri-operative mortality [163, 164], overall mortality [165], and CSM [138, 166-168]. Only the age-adjusted version of the CCI has been widely studied in patients with BC and found to be an independent prognostic factor for peri-operative mortality [163, 164], overall mortality [165], and CSM [138, 166-168]. Only the age-adjusted version of the CCI was correlated with both cancer-specific and other-cause mortality [169]. The age-adjusted CCI (Table 5.2) is the most widely used comorbidity index in cancer for estimating long-term survival and is easily calculated [170].

Health assessment of oncology patients must be supplemented by measuring their activity level. Extermann et al. have shown that there is no correlation between morbidity and competitive activity level [171]. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores and Karnofsky index have been validated to measure patient activity [172]. Performance score is correlated with patient OS after RC [167] and palliative chemotherapy [173-175].

Patients who have screened positive for frailty or cognitive impairment benefit from an assessment by a geriatrician. This allows identification of geriatric syndromes and any scope for optimisation. The most complete protocol is the Comprehensive Geriatric Assessment (CGA) [176] which is useful in the care of cancer patients [177]. In BC, the CGA has been used to adapt gemcitabine chemotherapy in previously untreated older patients with advanced BC [178].
Table 5.2: Calculation of the Charlson Comorbidity Index

<table>
<thead>
<tr>
<th>Number of points</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50–60 years (50 points)</td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
</tr>
<tr>
<td></td>
<td>Peripheral vascular insufficiency</td>
</tr>
<tr>
<td></td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td></td>
<td>Dementia</td>
</tr>
<tr>
<td></td>
<td>Chronic lung disease</td>
</tr>
<tr>
<td></td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td></td>
<td>Ulcer disease</td>
</tr>
<tr>
<td></td>
<td>Mild liver disease</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
</tr>
<tr>
<td>2</td>
<td>61–70 years (10 points)</td>
</tr>
<tr>
<td></td>
<td>Hemiplegia</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe kidney disease</td>
</tr>
<tr>
<td></td>
<td>Diabetes with organ damage</td>
</tr>
<tr>
<td></td>
<td>Tumours of all origins</td>
</tr>
<tr>
<td>3</td>
<td>71–80 years (15 points)</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe liver disease</td>
</tr>
<tr>
<td>4</td>
<td>81–z years (20 points)</td>
</tr>
<tr>
<td>5</td>
<td>&gt; 90 years (25 points)</td>
</tr>
<tr>
<td>6</td>
<td>Metastatic solid tumours</td>
</tr>
<tr>
<td></td>
<td>AIDS</td>
</tr>
</tbody>
</table>

Interpretation:
1. Calculate Charlson Comorbidity Score or Index = i
   a. Add comorbidity score to age score
   b. Total denoted as ‘i’ in the Charlson Probability calculation (see below).
      \[ i = \text{sum of comorbidity score to age score} \]
2. Calculate Charlson Probability (10-year mortality = Y)
   a. Calculate \( Y = 10^i \times 0.9 \)
   b. Calculate \( Z = 0.983^Y \) (where \( Z \) is the 10-year survival)

5.3.3 **Summary of evidence and guidelines for comorbidity scales**

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronological age is of limited relevance.</td>
<td>3</td>
</tr>
<tr>
<td>It is important to screen for frailty and cognitive impairment and provide a Comprehensive Geriatric Assessment (CGA) where optimisation is needed.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base the decision on bladder-sparing treatment or radical cystectomy in older/frail patients with invasive bladder cancer on tumour stage and frailty.</td>
<td>Strong</td>
</tr>
<tr>
<td>Assess comorbidity by a validated score, such as the Charlson Comorbidity Index. The American Society of Anesthesiologists score should not be used in this setting (see Section 5.3.2).</td>
<td>Strong</td>
</tr>
</tbody>
</table>
6. MARKERS

6.1 Introduction
Both patient and tumour characteristics guide treatment decisions and prognosis of patients with MIBC.

6.2 Prognostic markers

6.2.1 Histopathological and clinical markers
The most important histopathological prognostic variables after RC and LN dissection are tumour stage and LN status [179]. In addition, other histopathological parameters of the RC specimen have been associated with prognosis.

The value of lymphovascular invasion was reported in a systematic review and meta-analysis including 78,000 patients from 65 studies treated with RC for BC [180]. Lymphovascular invasion was present in 35% of the patients and correlated with a 1.5-fold higher risk of recurrence and CSM, independent of pathological stage and peri-operative chemotherapy. This correlation was even stronger in those patients with node-negative disease [181].

In a systematic review and meta-analysis including 23 studies and over 20,000 patients, the presence of concomitant CIS in the RC specimen was associated with a higher odds ratio (OR) of ureteral involvement (pooled OR: 4.51, 2.59–7.84). Concomitant CIS was not independently associated with OS, recurrence-free survival (RFS) and DSS in all patients, but in patients with organ-confined disease concomitant CIS was associated with worse RFS (pooled HR: 1.57, 1.12–2.21) and CSM (pooled HR: 1.51, 1.001–2.280) [181].

Tumour location has been associated with prognosis. Tumours located at the bladder neck or trigone of the bladder appear to have an increased likelihood of nodal metastasis (OR: 1.83, 95% CI: 1.11–2.99) and have been associated with decreased survival [179, 182-184].

Prostatic urethral involvement at the time of RC was also found to be associated with worse survival outcomes. In a series of 995 patients, prostatic involvement was recorded in 31% of patients. The 5-year CSS in patients with CIS of the prostatic urethra was 40%, whilst the prognosis of patients with UC invading the prostastic stroma was worse with a 5-year CSS of only 12% [185].

Neutrophil-to-lymphocyte ratio (NLR) has emerged as a prognostic factor in UUT tumours [1] and other non-urological malignancies. In a pooled analysis of 21 studies analysing the prognostic role of NLR in BC, the authors correlated elevated pre-treatment NLR with OS, RFS and disease-free survival (DFS) in both localised and metastatic disease [186]. In contrast, a secondary analysis of the Southwest Oncology Group (SWOG) 8710 trial, a randomised phase III trial assessing cystectomy ± NAC in patients with MIBC, suggests that NLR is neither a prognostic nor a predictive biomarker for OS in MIBCs [187].

In patients with LN-positive disease, the American Joint Committee on Cancer (AJCC)-TNM staging system provides 3 subcategories. In addition, several other prognostic LN-related parameters have been reported. These include, but are not limited to, the number of positive LNs, the number of LNs removed, LN density (the ratio of positive LNs to the number of LNs removed) and extranodal extension. In a systematic review and meta-analysis, it was reported that LN density was independently associated with OS (HR: 1.45, 95%, CI: 1.11–1.90) [188]. It has been suggested that LN density outperforms the AJCC-TNM staging system for LN-positive disease in terms of prognostic value [189]. However, in spite of these studies supporting the use of LN density, LN density relies on the number of LNs removed which, in turn, is subject to surgical and pathological factors. This makes the concept of LN density difficult to apply uniformly [190].

Two studies investigated whether any of the reported LN-related parameters may be superior to the routinely used AJCC-TNM staging system [190, 191]. Whilst the conclusion was that the AJCC-TNM staging system for LN status did not perform well, none of the other tested variables outperformed the AJCC system.

6.2.2 Molecular markers

6.2.2.1 Molecular subtypes based on the Cancer Genome Atlas cohort
The updated Cancer Genome Atlas (TCGA) reported on 412 MIBCs and identified two main groups; luminal and basal-squamous - consisting of five mRNA expression-based molecular subtypes including luminal-papillary, luminal-infiltrated, luminal; basal-squamous; and neuronal, a subtype associated with poor survival in which the majority of tumours do not have small cell or neuroendocrine histology. Each subtype is associated with distinct mutational profiles, histopathological features and prognostic and treatment implications [192].

The basal-squamous subtype is characterised by expression of basal keratin markers, immune infiltrates and is felt to be chemosensitive. The different luminal subtypes are characterised by fibroblast growth factor receptor 3 (FGFR3) alterations (luminal-papillary), epithelial-mesenchymal transition (EMT) markers (luminal-infiltrated) and may be associated with chemotherapy resistance [65, 66, 192, 193].
In 2019, a consensus on molecular subtype classification was reported [194]. The authors analysed 1,750 MIBC transcriptomic profiles from 18 datasets and identified six MIBC molecular classes that reconcile all previously published classification schemes. The molecular subgroup classes include luminal papillary (LumP), luminal non-specified (LumNS), luminal unstable (LumU), stroma-rich, basal/squamous (Ba/Sq), and neuroendocrine-like (NE-like). Each class has distinct differentiation patterns, oncogenic mechanisms, tumour micro-environments and histological and clinical associations. However, the authors stressed that consensus was reached for biological rather than clinical classes. Therefore, at this time, the classification should be considered as a research tool for retrospective and prospective studies until future studies establish how these molecular subgroups can be used best in a clinical setting.

Molecular classification of MIBC is still evolving and treatment tailored to molecular subtype is not a standard yet. A novel 12-gene signature derived from patients in the TCGA utilising published gene signatures has been developed and externally validated to predict OS in MIBC [195]. Interestingly, a recently published analysis of molecular subtyping in MIBC demonstrated that although molecular subtypes reflect the heterogeneity of bladder tumours and are associated with tumour grade, clinical parameters outperformed subtypes for predicting outcome [196]. In the coming years, new insights into BC carcinogenesis may change our management of the disease and our ability to better predict outcomes.

### 6.3 Predictive markers

#### 6.3.1 Clinical and histopathological markers

Based on retrospective data only, patients with secondary MIBC have a worse response to NAC compared to patients with primary MIBC [197]. Pietzak et al. retrospectively analysed clinico-pathologic outcomes comparing 245 patients with clinical T2–4a N0M0 primary MIBC and 43 patients with secondary MIBC treated with NAC and RC. They found that patients with secondary MIBC had lower pathologic response rates following NAC than those with primary MIBC (univariable 26% vs. 45%, multivariable OR: 0.4 [95% CI: 0.18–0.84, p = 0.02]). They also found that MIBC patients progressing after NAC had worse CSS as compared to patients treated with cystectomy alone (p = 0.002).

Variant histologies and non-UC have also been linked to worse outcomes after NAC, but there is, as yet, insufficient data to conclude that they can be considered as predictive markers [198].

#### 6.3.2 Molecular markers

Several predictive biomarkers have been investigated such as serum vascular endothelial growth factor [199], circulating tumour cells as well as defects in DNA damage repair (DDR) genes including ERCC2, ATM, RB1 and FANCC that may predict response to cisplatin-based NAC [200, 201]. More recently, alterations in FGFR3 including both mutations and gene fusions have been shown to be associated with response to FGFR inhibitors [202, 203].

More recent efforts have focused on markers for predicting response to immune checkpoint inhibition. Programmed death-ligand 1 (PD-L1) expression by immunohistochemistry has been evaluated in several studies with mixed results which may in part be related to the use of different antibodies and various scoring systems evaluating different compartments i.e., tumour cells, immune cells, or both. The major limitation of PD-L1 staining relates to the significant proportion of PD-L1-negative patients that respond to immune checkpoint blockade. For example, in the IMVigor 210 phase II study of atezolizumab in patients with advanced/metastatic UC who progressed after platinum-based chemotherapy, responses were seen in 18% of patients with low/no PD-L1 expression [204]. At present, the only indication for PD-L1 testing relates to the use of immune checkpoint inhibitors as monotherapy in patients with locally advanced or metastatic UC unfit for cisplatin-containing chemotherapy who have not received prior therapy. In this setting, pembrolizumab or atezolizumab should only be used in patients unfit for cisplatin-containing chemotherapy whose tumours overexpress PD-L1 (i.e., Combined Positive Score [CPS] ≥ 10 using the 22C3 assay for pembrolizumab and tumour-infiltrating immune cells [IC] covering ≥ 5% of the tumour area using the SP142 assay for atezolizumab) [205].

Urothelial cancer is associated with a high tumour mutational burden (TMB) [206]. Both predicted neoantigen burden and tumour mutational burden have been associated with response to immune checkpoint inhibitors in metastatic BC [204, 207]. Conflicting results have been seen in studies evaluating immune checkpoint inhibitors in the neoadjuvant setting with the Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE)-01 study utilising pembrolizumab demonstrating an association of high TMB with response while there was no association with atezolizumab in the Phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in MIBC (ABACUS) [208, 209].
Other markers that have been evaluated in predicting response to immune checkpoint inhibitors include molecular subtypes as discussed earlier, CD8 expression by immunohistochemistry and other immune gene cell signatures. Recent work has focused on the importance of stroma including the role of TGFβ in predicting response to immune checkpoint blockade [210, 211]. Although promising, there are currently no validated predictive molecular markers that are routinely used in clinical practice. Further validation studies are awaited.

### 6.4 Conclusion

The updated Cancer Genome Atlas and other efforts have refined our understanding of the molecular underpinnings of bladder cancer biology. Molecular subtypes, immune gene signatures as well as stromal signatures may ultimately have an important role in predicting response to immunotherapy. Although PD-L1 expression by immunohistochemistry and TMB have demonstrated predictive value in certain settings, additional studies are needed. Prospectively validated prognostic and predictive molecular biomarkers will present valuable adjuncts to clinical and pathological data, but large phase III randomised controlled trials (RCTs) with long-term follow-up will be needed to clarify the many questions remaining.

### 6.5 Summary of evidence and recommendations for urothelial markers

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is insufficient evidence to use TMB, molecular subtypes, immune or other gene expression signatures for the management of patients with urothelial cancer.</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate PD-L1 expression (by immunohistochemistry) to determine the potential for use of pembrolizumab or atezolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who are unfit for cisplatin-based chemotherapy.</td>
<td>Weak</td>
</tr>
<tr>
<td>Evaluate for FGFR2/3 genetic alterations for the potential use of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma who have progressed following platinum-containing chemotherapy (including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy).</td>
<td>Weak</td>
</tr>
</tbody>
</table>

### 7. DISEASE MANAGEMENT

#### 7.1 Neoadjuvant therapy

##### 7.1.1 Introduction

The standard treatment for patients with urothelial MIBC and MIBC with variant histologies is RC. However, RC only provides 5-year survival in about 50% of patients [212-216]. To improve these results in patients with cN0M0 disease, cisplatin-based NAC has been used since the 1980s [212-218].

##### 7.1.2 Role of cisplatin-based chemotherapy

There are theoretical advantages and disadvantages of administering chemotherapy before planned definitive surgery to patients with resectable muscle-invasive UC of the bladder and cN0M0 disease:

- Chemotherapy is delivered at the earliest time-point, when the burden of micrometastatic disease is expected to be low.
- Potential reflection of *in-vivo* chemosensitivity.
- Tolerability of chemotherapy and patient compliance are expected to be better pre-cystectomy.
- Patients may respond to NAC and have a favourable pathological response as determined mainly by achieving ypT0, ≤ ypT1, ypN0 and negative surgical margins.
- Delayed cystectomy might compromise the outcome in patients not sensitive to chemotherapy [219-221]. However, there are no prospective trials indicating that delayed surgery due to NAC has a negative impact on survival. In the recently reported French Genito-Urinary Group and the French Association of Urology (GETUG/AFU) V05 Randomized Phase III VESPER trial, comparing gemcitabine/cisplatin (GC) vs. high-dose-intensity methotrexate, vinblastine, doxorubicine and cisplatin (HD-MVAC) in the peri-operative setting, approximately 90% of patients proceeded to surgery after neoadjuvant dose-dense MVAC (ddMVAC) or GC (median delay of surgery was 48 days for GC and 51 days for ddMVAC) [222].
• Neoadjuvant chemotherapy does not seem to affect the outcome of surgical morbidity. In one
randomised trial the same distribution of grade 3–4 post-operative complications was seen in both
treatment arms [223]. In the combined Nordic trials (n = 620), NAC did not have a major adverse effect
on the percentage of performable cystectomies. The cystectomy frequency was 86% in the experimental
arm and 87% in the control arm with 71% of patients receiving all three chemotherapy cycles [224].
• Clinical staging using bimanual palpation, CT or MRI may result in over- and understaging and have a
staging accuracy of only 70% [78]. Overtreatment is a possible negative consequence.
• Gender may have an impact on chemotherapeutic response and oncologic outcomes [225, 226].
• Neoadjuvant chemotherapy should only be used in patients eligible for cisplatin-combination
chemotherapy; other combinations (or monotherapies) are inferior in metastatic BC and have not been
fully tested in a neoadjuvant setting [223, 227-235].

7.1.2.1 Summary of available data
Several randomised phase III trials addressed the potential survival benefit of NAC administration [223, 227-
232, 236-240]. The main differences in trial designs were the type of chemotherapy (i.e., single-agent cisplatin
or combination chemotherapy) and the number of cycles provided. Patients had to be fit for cisplatin. Since
these studies differed considerably for patient numbers, patient characteristics (e.g., clinical T-stages included)
and the type of definitive treatment offered (cystectomy and/or RT), pooling of results was not possible.

Three meta-analyses were undertaken to establish if NAC prolongs survival [233-235]. In a
meta-analysis, published in 2005 [235] with updated patient data from 11 randomised trials (n = 3,005),
a significant survival benefit was shown in favour of NAC. The most recent meta-analysis included four
additional randomised trials, and used the updated results from the Nordic I, Nordic II, and BA06 30894 trials
including data from 427 new patients and updated information from 1,596 patients. The results of this analysis
confirmed the previously published data and showed an 8% absolute improvement in survival at five years
with a number needed-to-treat of 12.5 [241]. Only cisplatin-combination chemotherapy with at least one
additional chemotherapeutic agent resulted in a meaningful therapeutic benefit [233, 235]; the regimens tested
were methotrexate, vinblastine, adriamycin (epirubicin) plus cisplatin (MVA(E)C), cisplatin, methotrexate plus
vinblastine (CMV), cisplatin plus methotrexate (CM), cisplatin plus adriamycin and cisplatin plus 5-fluorouracil
(5-FU) [242].

The updated analysis of a large phase III RCT [227] with a median follow-up of eight years
confirmed previous results and provided additional findings:
• 16% reduction in mortality risk;
• improvement in 10-year survival from 30% to 36% with neoadjuvant CMV;
• benefit with regard to distant metastases;
• the addition of neoadjuvant CMV provided no benefit for locoregional control and locoregional DFS,
independent of the definitive treatment.

More modern chemotherapeutic regimens such as GC have shown similar pT0/pT1 rates as methotrexate,
vinblastine, adriamycin plus cisplatin in retrospective series and pooled data analyses [242-245]. Modified
ddMVAC was tested in two small single-arm phase II studies demonstrating high rates of pathologic complete
remission [246, 247]. Moreover, a large cross-sectional analysis showed higher rates of down-staging and
pathological complete response for ddMVAC [248]. The recently reported results from the GETUG/AFU V05
VESPER randomised trial of ddMVAC vs. cisplatin and cisplatin as peri-operative chemotherapy in patients
with MIBC demonstrated similar pathologic response rates (ypT0N0) in patients treated with neoadjuvant
ddMVAC or GC of 42% and 36%, respectively (p = 0.2). An organ-confined status (< ypT3pN0) was obtained
in 154 (77%) and 124 (63%) patients, respectively (p = 0.001). Dose-dense MVAC was associated with more
severe asthenia and gastrointestinal side effects than GC. Although a higher local control rate (complete
pathological response, tumour down-staging, or organ confined) was observed in the ddMVAC arm (p = 0.021),
the primary endpoint of PFS at three years is not yet mature [222]. Another dose-dense regimen using cisplatin/
gemcitabine was reported in two small phase II trials [249, 250]. While pathological response rates (< pT2)
in the range of 45%–57% were achieved, one trial had to be closed prematurely due to high rates of severe
vascular events [249]. This approach is therefore not recommended outside of clinical trials.

As an alternative to the standard dose of cisplatin-based NAC with 70 mg/m² on day 1, split-dose
modifications regimens are often used with 35 mg/m² on days 1+8 or days 1+2. In a retrospective analysis
the standard schedule was compared to a split-dose schedule in terms of complete and partial pathological
response. A lower number of complete and partial response rates was seen in the split-dose group, but these
results were not statistically significant [251].
There seem to be differences in the outcomes of patients treated with NAC for primary or secondary MIBC. However, in the absence of prospective data, patients with secondary MIBC should be treated similarly to those presenting with primary MIBC [197].

It is unclear, if patients with non-UC histology will also benefit from NAC. A retrospective analysis demonstrated that patients with neuroendocrine tumours had improved OS and lower rates of non-organ-confined disease when receiving NAC. In case of micropapillary differentiation, sarcomatoid differentiation and adenocarcinoma, lower rates of non-organ confined disease were found, but no statistically significant impact on OS. Patients with SCC did not benefit from NAC [252].

A retrospective analysis assessed the use of NAC in MIBC based on data from the U.S. National Cancer Database [253]. Only 19% of all patients received NAC before RC (1,619 of 8,732 patients) and no clear survival advantage for NAC following propensity score adjustment was found despite efforts to include patients based on SWOG 8710 study criteria [223]. These results have to be interpreted with caution, especially since no information was available for the type of NAC applied. Such analyses emphasise the importance of pragmatically designed studies that reflect real-life practice.

7.1.3 The role of imaging and predictive biomarkers
Data from small imaging studies aiming to identify responders in patients treated with NAC suggest that response after two cycles of treatment is predictive of outcome. Although mpMRI has the advantage of better resolution of the bladder wall tissue planes as compared to CT, it is not ready yet for standard patient care. However, bladder mpMRI may be useful to inform on tumour stage after TURB and response to NAC [254]. So far PET/CT, MRI or DCE-MRI cannot accurately assess treatment response [255-258]. To identify progression during NAC imaging is being used in many centres notwithstanding the lack of supporting evidence. For responders to NAC, especially in those with a complete response (pT0 N0), treatment has a major positive impact on OS [259, 260]. Therefore, reliable predictive markers to identify patients most likely to benefit from chemotherapy are needed. Molecular tumour profiling might guide the use of NAC in the future but, as yet, this is not applicable in routine practice [261-263] (see Chapter 6 - Markers).

7.1.4 Role of neoadjuvant immunotherapy
Inhibition of programmed death receptor-1 (PD-1)/PD-L1 checkpoint has demonstrated significant benefit in patients with unresectable and metastatic BC in the second-line setting and in platinum-ineligible PD-L1+ patients as first-line treatment using different agents. Checkpoint inhibitors are increasingly tested also in the neoadjuvant setting; either as monotherapy or in combination with chemotherapy or CTLA-4 checkpoint inhibition. Data from two phase II trials have been presented with encouraging results [208, 209]. The results of the phase II trial using the PD-1 inhibitor pembrolizumab reported a complete pathological remission (pT0) in 42% and pathological response (< pT2) in 54% of patients, whereas in the single-arm phase II trial with atezolizumab a pathologic complete response rate of 31% was reported. However, immunotherapy is not yet approved in the neoadjuvant setting.

7.1.5 Summary of evidence and guidelines for neoadjuvant therapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival (OS) (5–8% at five years).</td>
<td>1a</td>
</tr>
<tr>
<td>Neoadjuvant treatment has a major impact on OS in patients who achieve ypT0 or at least ypT2.</td>
<td>2</td>
</tr>
<tr>
<td>Currently immunotherapy with checkpoint inhibitors as monotherapy, or in different combinations, is being tested in phase II and III trials. Initial results are promising.</td>
<td>-</td>
</tr>
<tr>
<td>There are still no tools available to select patients who have a higher probability of benefitting from NAC. In the future, genetic markers in a personalised medicine setting might facilitate the selection of patients for NAC and differentiate responders from non-responders.</td>
<td>-</td>
</tr>
<tr>
<td>Neoadjuvant chemotherapy has its limitations regarding patient selection, current development of surgical techniques and current chemotherapy combinations.</td>
<td>3</td>
</tr>
</tbody>
</table>
Recommendations | Strength rating
---|---
Offer neoadjuvant chemotherapy (NAC) for T2–T4a, cN0 M0 bladder cancer. In this case, always use cisplatin-based combination therapy. | Strong
Do not offer NAC to patients who are ineligible for cisplatin-based combination chemotherapy. | Strong
Only offer neoadjuvant immunotherapy to patients within a clinical trial setting. | Strong

### 7.2 Pre- and post-operative radiotherapy in muscle-invasive bladder cancer

#### 7.2.1 Post-operative radiotherapy

Given the high rates of local-regional failure after RC in patients with locally advanced (pT3–4) BC, estimated at ~30%, as well as the high risk of distant failure and poor survival for these patients, there is an interest in adjuvant therapies that address both the risk of local and distant disease. Data on adjuvant RT after RC are limited and further prospective studies are needed, but a more recent phase II trial compared adjuvant sequential chemotherapy and radiation vs. adjuvant chemotherapy alone in 120 patients with locally advanced disease and negative margins after RC (with one or more risk factors: ≥ pT3b, grade 3, or node-positive), in a study population with 53% UC and 47% SCC. Addition of adjuvant RT to chemotherapy alone was associated with a statistically significant improvement in local relapse-free survival (at 2 years 96% vs. 69% favouring the addition of RT). Disease-free survival and OS also favoured the addition of RT, but those differences were not statistically significant and the study was not powered for those endpoints. Late-grade ≥ 3 gastrointestinal toxicity in the chemoradiation arm was low (7% of patients) [264].

A 2019 systematic review evaluating the efficacy of adjuvant radiation for BC or UTUC found no clear benefit of adjuvant radiation following radical surgery (e.g., cystectomy), although the combination of adjuvant radiation with chemotherapy may be beneficial in locally advanced disease [265].

While there are no conclusive data demonstrating improvements in OS it is reasonable to consider adjuvant radiation in patients with pT3/pT4 pN0–2 urothelial BC following RC, although this approach has been evaluated in only a limited number of studies. Radiation fields should encompass areas at risk for harbouring residual microscopic disease based on pathologic findings at surgery and may include cystectomy bed and pelvic LNs. Doses in the range of 45 to 50.4 Gy may be considered. For patients who have not had prior NAC, it may be reasonable to sandwich adjuvant radiation between cycles of adjuvant chemotherapy. The safety and efficacy of concurrent radiosensitising chemotherapy in the adjuvant setting needs further study.

#### 7.2.2 Pre-operative radiotherapy

To date, six RCTs have been published investigating pre-operative RT, although all are from several decades ago. In the largest trial, pre-operative RT at a dose of 45 Gy was used in patients with muscle-invasive tumours resulting in a significant increase in pathological complete response (9% to 34%) in favour of pre-operative RT, which was also a prognostic factor for survival [266]. The OS data were difficult to interpret since chemotherapy was used in a subset of patients only and more than 50% of patients (241/475) did not receive the planned treatment and were excluded from the final analyses. Two smaller studies using a dose of 20 Gy showed only a small survival advantage in ≥ T3 tumours [267, 268]. Two other small trials confirmed down-staging after pre-operative RT [269, 270].

A meta-analysis of five RCTs showed a difference in 5-year survival (OR: 0.71, 95% CI: 0.48–1.06) in favour of pre-operative RT [271]. However, the meta-analysis was potentially biased by data from the largest trial in which patients were not given the planned treatment. When the largest trial was excluded from the analysis, the OR became 0.94 (95% CI: 0.57–1.55), which was not significant.

A more recent RCT, comparing pre-operative vs. post-operative RT and RC (n = 100), showed comparable OS, DFS and complication rates [272]. Approximately half of these patients had UC, while the other half had SCC.

In general, such older data is limited in being able to provide a robust evidence base for modern guideline recommendations.
7.2.3  **Summary of evidence and guidelines for pre- and post-operative radiotherapy**

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>No contemporary data exists to support that pre-operative RT for operable MIBC increases survival.</td>
<td>2a</td>
</tr>
<tr>
<td>Pre-operative RT for operable MIBC, using a dose of 45–50 Gy in fractions of 1.8–2 Gy, results in down-staging after 4 to 6 weeks.</td>
<td>2</td>
</tr>
<tr>
<td>Limited high-quality evidence supports the use of pre-operative RT to decrease local recurrence of MIBC after radical cystectomy.</td>
<td>3</td>
</tr>
<tr>
<td>Addition of adjuvant RT to chemotherapy is associated with an improvement in local relapse-free survival following cystectomy for locally-advanced bladder cancer (pT3b–4, or node-positive).</td>
<td>2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer pre-operative radiotherapy (RT) for operable muscle-invasive bladder cancer since it will only result in down-staging, but will not improve survival.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not offer pre-operative RT when subsequent radical cystectomy (RC) with urinary diversion is planned.</td>
<td>Strong</td>
</tr>
<tr>
<td>Consider offering adjuvant radiation in addition to chemotherapy following RC, based on pathologic risk (pT3b–4 or positive nodes or positive margins).</td>
<td>Weak</td>
</tr>
</tbody>
</table>

7.2.4  **EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer** [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidates for curative treatment, such as cystectomy or bladder preservation, should be clinically assessed by at least an oncologist, a urologist and a neutral HCP such as a specialist nurse.</td>
</tr>
<tr>
<td>When assessing patient eligibility for bladder preservation, the likelihood of successful debulking surgery should be taken into consideration (optimal debulking).</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

HCP = healthcare professional.

7.3  **Radical surgery and urinary diversion**

7.3.1  **Removal of the tumour-bearing bladder**

7.3.1.1  **Introduction**

Radical cystectomy is the standard treatment for localised MIBC in most Western countries [212, 273]. Increased recognition of the central patient role as a healthcare consumer and a greater focus on patients’ QoL contributed to an increasing trend of utilising bladder-preserving treatment modalities, such as radio- and/or chemotherapy (see Section 7.5). Performance status and life expectancy influence the choice of primary management as well as the type of urinary diversion with RC being reserved for patients with a longer life expectancy without concomitant disease and a better PS. The value of assessing overall health before proceeding with surgery was emphasised in a multivariate analysis [138]. The analysis found an association between comorbidity and adverse pathological- and survival outcomes following RC [138]. Performance status and comorbidity have a different impact on treatment outcomes and must be evaluated independently [171].

7.3.1.2  **Radical cystectomy: timing**

A population-based study utilising the U.S. SEER database analysed patients who underwent a RC between 1992 and 2001 and the authors concluded that a delay of > 12 weeks has a negative impact on outcome and should be avoided [274]. Moreover, the SEER analysis did not show any significant utilisation and timing differences between men and women. A 2020 meta-analysis including 19 studies confirmed these findings, showing that a longer delay of RC after diagnosis (> 3 months) was found to have a detrimental effect on OS (HR: 1.34, 95% CI: 1.18–1.53). The authors highlight the lack of standardisation how delays were defined in the included studies which prohibited defining a clear cut-off time, although most studies used a cut-off of < 3 months [275]. Overall conclusion was that BC patients scheduled for RC should be treated without delays to maximise survival.
7.3.2  **Radical cystectomy: indications**

Traditionally, RC was recommended in patients with T2–T4a, N0–Nx, M0 disease [273]. Other indications include recurrent high-risk non-muscle-invasive tumours, BCG-refractory, BCG-relapsing and BCG-unresponsive NMIBC (see EAU Guidelines on Non-muscle-invasive Bladder Cancer [2]), as well as extensive papillary disease that cannot be controlled with TURB and intravesical therapy alone.

Salvage cystectomy is indicated in non-responders to conservative therapy, recurrence after bladder-sparing treatment, and non-UC. It is also used as a purely palliative intervention, including for fistula formation, pain and recurrent visible haematuria (see Section 7.4.1 - Palliative cystectomy).

7.3.3  **Radical cystectomy: technique and extent**

Different approaches have been described to improve voiding and sexual function in patients undergoing RC for BC. No consensus exists regarding which approach preserves function best. Concern remains regarding the impact of “sparing-techniques” on oncological outcomes.

To determine the effect of sexual function-preserving cystectomy (SPC) on functional and oncological outcomes the Panel undertook two systematic reviews addressing sparing techniques in men and women [276, 277].

In men, standard RC includes removal of the bladder, prostate, seminal vesicles, distal ureters, and regional LNs. In women, standard RC includes removal of the bladder, the entire urethra and adjacent vagina, uterus, distal ureters, and regional LNs [278].

7.3.3.1  **Radical cystectomy in men**

Four main types of sexual-preserving techniques have been described:

1. **Prostate sparing cystectomy**: part of or the whole prostate is preserved including seminal vesicles, vas deferens and neurovascular bundles.
2. **Capsule sparing cystectomy**: the capsule or peripheral part of the prostate is preserved with adenoma (including prostatic urethra) removed by TURP or en bloc with the bladder. Seminal vesicles, vas deferens and neurovascular bundles are also preserved.
3. **Seminal sparing cystectomy**: seminal vesicles, vas deferens and neurovascular bundles are preserved.
4. **Nerve-sparing cystectomy**: the neurovascular bundles are the only tissue left in place.

Twelve studies recruiting a total of 1,098 patients were identified, including nine comparative studies [279-289] and three single-arm case series [290-292]. In the majority of cases, an open surgical approach was used and the urinary diversion of choice was an orthotopic neobladder. Median follow-up was longer than three years in nine studies, with three studies presenting results with a median follow-up longer than five years.

The majority of the studies included patients who were potent pre-operatively with organ-confined disease without tumour in the bladder neck and/or prostatic urethra. Prostate cancer was ruled out in all of the SPC techniques, except in nerve-sparing cystectomy.

Oncological outcomes did not differ between groups in any of the comparative studies that measured local recurrence, metastatic recurrence, DSS and OS, at a median follow-up of three to five years. Local recurrence after SPC was commonly defined as any UC recurrence below the iliac bifurcation within the pelvic soft tissue and ranged from 1.2–61.1% vs. 16–55% in the control group. Metastatic recurrence ranged from 0–33.3%.

For techniques preserving prostatic tissue (prostate- or capsule-sparing), rates of incidental prostate cancer in the intervention group ranged from 0–15%. In no case was incidental prostate cancer with ISUP grade ≥ 4 reported.

Post-operative potency was significantly better in patients who underwent any type of sexual-preserving technique compared to conventional RC (p < 0.05), ranging from 80–90%, 50–100% and 29–78% for prostate-, capsule- or nerve-sparing techniques, respectively. Data did not show superiority of any sexual-preserving technique.

Urinary continence, defined as the use of “no pads” in the majority of studies, ranged from 88–100% (day-time continence) and from 31–96% (night-time continence) in the prostate-sparing cystectomy patients. No major impact was shown with regard to continence rates for any of the three approaches.

The evidence base suggests that these procedures may yield better sexual outcomes than standard RC without compromising oncological outcomes. However, the overall quality of the evidence was moderate, and hence if a sexual-preserving technique is offered, patients must be carefully selected, counselled and closely monitored.
7.3.3.1 Summary of evidence and recommendations for sexual-preserving techniques in men

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The majority of patients motivated to preserve their sexual function will benefit from sexual-preserving techniques.</td>
<td>2a</td>
</tr>
<tr>
<td>None of the sexual-preserving techniques (prostate/capsule/seminal/nerve-sparing) have shown to be superior, and no particular technique can be recommended.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer sexual-preserving radical cystectomy to men as standard therapy for muscle-invasive bladder cancer.</td>
<td>Strong</td>
</tr>
<tr>
<td>Offer sexual-preserving techniques to men motivated to preserve their sexual function since the majority will benefit.</td>
<td>Strong</td>
</tr>
<tr>
<td>Select patients based on:</td>
<td>Strong</td>
</tr>
<tr>
<td>• organ-confined disease;</td>
<td></td>
</tr>
<tr>
<td>• absence of any kind of tumour at the level of the prostate, prostatic urethra or bladder neck.</td>
<td></td>
</tr>
</tbody>
</table>

7.3.3.2 Radical cystectomy in women

Pelvic floor disorders, sexual and voiding dysfunction in female patients are prevalent after RC [293]. As part of the pre-operative evaluation a gynaecological history should be obtained and patients should be counselled on the potential negative impact of RC on sexual function and/or vaginal prolapse. Most importantly, a history of cervical cancer screening, abnormal vaginal bleeding and a family history of breast and/or ovarian cancer should be recorded, as well as ruling out possible pelvic organ prolapse. Equally important is screening for sexual and urinary function and prolapse post-operatively. Better imaging modalities, increased knowledge of the function of the pelvic structures and improved surgical techniques have enabled less destructive methods for treating high-risk BC.

Pelvic organ-preserving techniques involve preserving the neurovascular bundle, vagina, uterus, ovaries or variations of any of the stated techniques. From an oncological point of view, concomitant malignancy in gynaecological organs is rare and local recurrences reported after RC are infrequent [294, 295]. In premenopausal women, by preserving ovaries, hormonal homeostasis will be preserved, decreasing risk of cognitive impairment, cardiovascular diseases and loss of bone density. In case of an increased risk of hereditary breast or ovarian cancer (i.e., BRCA1/2 mutation carriers or patients with Lynch syndrome), salpingooophorectomy should be advised after childbearing and to all women over 40 years of age [296]. On the other hand, preservation of the uterus and vagina will provide the necessary support for the neobladder, thereby reducing the risk of urinary retention. It also helps to avoid post-operative prolapse as removal of the uterus predisposes to an anterior or posterior vaginal prolapse. In case of an already existing prolapse of the uterus, either isolated or combined with a vaginal prolapse, removing the uterus will be beneficial. It is noteworthy that by resecting the vaginal wall, the vagina shortens which could potentially impair sexual satisfaction and function.

Based on retrospective low quality data only, a systematic review evaluating the advantages and disadvantages of sexual-function preserving RC and orthotopic neobladder in female patients concluded that in well-selected patients, sparing female reproductive organs during RC appears to be oncologically safe and provides improved functional outcomes [277].

Pelvic organ-preserving RC could be considered also in elderly and fragile patients having abdominal diversions. By reducing excision range, it might be beneficial from the point of reduced operating time, estimated blood loss and quicker bowel recovery [297].

7.3.3.2.1 Summary of evidence and recommendations for sexual-preserving techniques in women

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data regarding pelvic organ-preserving RC for female patients remain immature.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer pelvic organ-preserving radical cystectomy to women as standard therapy for muscle-invasive bladder cancer.</td>
<td>Strong</td>
</tr>
</tbody>
</table>
Offer sexual organ-preserving techniques to women motivated to preserve their sexual function since the majority will benefit. Weak

Select patients based on:
• absence of tumour in the area to be preserved to avoid positive soft tissue margins;
• absence of pT4 urothelial carcinoma. Strong

<table>
<thead>
<tr>
<th>7.3.4</th>
<th><strong>Lymphadenectomy: role and extent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Two important autopsy studies have been performed for RC so far. The first study showed that in 215 patients with MIBC and nodal dissemination, the frequency of metastasis was 92% in regional (perivesical or pelvic), 72% in retroperitoneal, and 35% in abdominal LNs. There was also a significant correlation between nodal metastases and concomitant distant metastases (p &lt; 0.0001). Approximately 47% of the patients had both nodal metastases and distant dissemination and only 12% of the patients had nodal dissemination as the sole metastatic manifestation [298].</td>
<td></td>
</tr>
<tr>
<td>The second autopsy study focused on the nodal yield when super-extended pelvic LND was performed. Substantial inter-individual differences were found with counts ranging from 10 to 53 nodes [299]. These findings demonstrate the limited utility of node count as a surrogate for extent of dissection.</td>
<td></td>
</tr>
<tr>
<td>Regional LNs have been shown to consist of all pelvic LNs below the bifurcation of the aorta [300-304]. Mapping studies also found that skipping lesions at locations above the bifurcation of the aorta without more distally located LN metastases is rare [304, 305].</td>
<td></td>
</tr>
<tr>
<td>The optimal extent of LND has not been established to date. Standard LND in BC patients involves removal of nodal tissue cranially up to the common iliac bifurcation, with the ureter being the medial border, and including the internal iliac, presacral, obturator fossa and external iliac nodes [306]. Extended LND includes all LNs in the region of the aortic bifurcation, and presacral and common iliac vessels medial to the crossing ureters. The lateral borders are the genitofemoral nerves, caudally the circumflex iliac vein, the lacunar ligament and the LN of Cloquet, as well as the area described for standard LND [306-310]. A super-extended LND extends cranially to the level of the inferior mesenteric artery [311, 312].</td>
<td></td>
</tr>
<tr>
<td>In order to assess how and if cancer outcome is influenced by the extent of LND in patients with clinical N0M0 MIBC, a systematic review of the literature was undertaken [313]. Out of 1,692 abstracts retrieved and assessed, nineteen studies fulfilled the review criteria [306-310, 312, 314-326]. All five studies comparing LND vs. no LND reported a better oncological outcome for the LND group. Seven out of twelve studies comparing (super)extended with limited or standard LND reported a beneficial outcome for (super)extended LND in at least a subset of patients which is in concordance with the findings of several other meta-analyses [327, 328]. No difference in outcome was reported between extended and super-extended LND in the two high-volume-centre studies identified [312, 324]. The LEA trial, a prospective phase III RCT, including 401 patients with a median follow-up of 43 months recently reported [329]. Extended LND failed to show a significant advantage (the trial was designed to show an absolute improvement of 15% in 5-year RFS by extended LND) over limited LND in RFS, CSS, and OS. Results from another large RCT on the therapeutic impact of the extent of LND are expected shortly.</td>
<td></td>
</tr>
<tr>
<td>It has been suggested that PFS as well as OS might be correlated with the number of LNs removed during surgery. Although there are no data from RCTs on the minimum number of LNs that should be removed, survival rates increase with the number of dissected LNs [330]. In retrospective studies removal of at least ten LNs has been postulated as sufficient for evaluation of LN status, as well as being beneficial for OS [331]. Submitting separate nodal packets instead of en bloc has shown significant increased total LN yield, but did not result in an increased number of positive LNs, making LN density an inaccurate prognosticator [332]. In conclusion, extended LND might have a therapeutic benefit compared to less extensive LND, but due to study bias no firm conclusions can be drawn [145, 313, 333].</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7.3.5</th>
<th><strong>Laparoscopic/robotic-assisted laparoscopic cystectomy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>A number of recent systematic reviews comparing open RC (ORC) and robot-assisted RC (RARC) reach similar conclusions; RARC has an approximately one-day shorter length of hospital stay (LOS) and less blood loss, but a longer operative time. Complication rates seem similar for both approaches but all published reviews suffer from low quality data.</td>
<td></td>
</tr>
<tr>
<td>In minimally-invasive cystectomy, with increasing age, LOS is markedly shorter; up to 2.56 days in patients over 80 years old [334].</td>
<td></td>
</tr>
</tbody>
</table>
Although the low level of evidence of the studies included in these reviews remains a major limitation, a recent Cochrane review incorporating data from all five published RCTs corroborates most findings [335]. Time to recurrence, positive surgical margin rates, grade 3–5 complications and QoL were comparable for RARC and ORC, whilst transfusion rate was likely lower after RARC. For other endpoints outcomes were uncertain due to study limitations.

The Pasadena Consensus Panel (a group of experts on RC, LND and urinary reconstruction) reached similar conclusions [336]. Additionally, they reported that RARC was associated with increased costs, although compared to laparoscopic RC (LRC) there are ergonomic advantages for the surgeon. For both techniques, surgeons’ experience and institutional volume strongly predicted outcome. According to the literature, proficiency is reached after 20–250 cases. However, after statistical modelling, the Pasadena Consensus Panel suggested 30 cases but they also concluded that challenging patients (high BMI, post chemotherapy or RT, pelvic surgery, T4 or bulky tumours or positive nodes) should be performed by experienced robotic surgeons only. Safety of RC after RT was confirmed by a small retrospective study (n = 46) [337]. In experienced hands the percentage of 90-day (major) complications after robotic cystectomy was independent of previous RT. A recent population-based study addressed benign uretero-enteric strictures, which appeared 5% higher after robotic - as compared to open surgery (15% vs. 9.5% at 12 months, p = 0.01) [338].

Positive surgical margins, as a surrogate for oncological outcome, are comparable between RARC and ORC, although with low certainty [335]. Recurrence-free survival, CSS and OS have been documented as similar in all RCTs including the largest RAZOR (Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer) trial (n = 302) [339]. Age over 70, poor PS and major complications were significant predictors of 36-month PFS whilst stage and positive margins were significant predictors of recurrence, PFS and OS. The surgical approach was not a significant predictor of any outcome. A larger (n = 595) single-centre study with a median follow-up of over five years also found comparable recurrence and survival data, including atypical recurrences (defined as one or a combination of the following: port-site metastasis or peritoneal carcinomatosis) [340]. However, recently, port-site metastases and atypical recurrences were reviewed by Mantica et al. [341]. Based on 31 studies and 6,720 evaluable patients, 105 patients (1.63%) were identified with an atypical recurrence, of which 63 (60%) were peritoneal carcinomatosis and 11 (10.5%) port-site metastases. The authors acknowledge, however, that these results may be linked to publication bias and retrospective study design of the included studies. Wei et al. detected residual cancer cells in pelvic washing specimens during or after, but not before, RARC in approximately half of the patients (9/17), which was associated with aggressive variant histology and cancer recurrence. These findings need confirmation in larger studies [342].

The largest RCT to date, the RAZOR trial, supports all of the above findings showing RARC to be non-inferior to ORC in terms of 2-year PFS (72.3% vs. 71.6%), adverse events (67% vs. 69%) and QoL [343].

Most reviewed series, including the RAZOR trial, offer extracorporeal reconstruction. Hussein et al. retrospectively compared extracorporeal reconstruction (n = 1,031) to intracorporeal reconstruction (n = 1,094); the latter was associated with a shorter operative time and fewer blood transfusions but more high-grade complications, which, again, decreased over time [344]. A recent retrospective report from a high-volume centre found less (major) complications after intracorporeal reconstruction (n = 301) as compared to extracorporeal reconstruction (n = 375) and open RC (n = 272) [345]. It is important to note that, although an intracorporeal neobladder is a very complex robotic procedure [346], the choice for neobladder or cutaneous diversion should not depend on the surgical approach.

7.3.5.1 Laparoscopic radical cystectomy versus robot-assisted radical cystectomy

For LRC a review including sixteen studies came to similar conclusions as described for RARC [346]. As compared to ORC, LRC had a significantly longer operative time, fewer overall complications, less blood transfusions and analgesic use, less blood loss and a shorter LOS. However, the review was limited by the inherent limitations of the included studies. Although this review also showed better oncological outcomes, these appeared comparable to ORC series in a large LRC multicentre study [347].

The CORAL study was a small single-centre RCT comparing open (n = 20) vs. robotic (n = 20) vs. laparoscopic (n = 19) RC [348, 349]. The 30-day complication rate was significantly higher in the open arm (70%) compared to the laparoscopic arm (26%). There was no difference between the 90-day Clavien complication rates in the three study arms. Limitations of this study include the small sample size, three different although experienced surgeons, and cross over between arms.
### 7.3.5.2 Summary of evidence and guidelines for laparoscopic/robotic-assisted laparoscopic cystectomy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robot-assisted radical cystectomy has longer operative time (1–1.5 hours) and major costs, but shorter length of hospital stay (1–1.5 days) and less blood loss compared to ORC.</td>
<td>1</td>
</tr>
<tr>
<td>Robotic cystectomy and open cystectomy may result in similar rates of (major) complications.</td>
<td>2</td>
</tr>
<tr>
<td>Most endpoints, if reported, including intermediate-term oncological endpoint and QoL, are not different between RARC and ORC.</td>
<td>2</td>
</tr>
<tr>
<td>Surgeons experience and institutional volume are considered the key factor for outcome of both RARC and ORC, not the technique.</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inform the patient of the advantages and disadvantages of open radical cystectomy (ORC) and robot-assisted radical cystectomy (RARC) to allow selection of the proper procedure.</td>
<td>Strong</td>
</tr>
<tr>
<td>Select experienced centres, not specific techniques, both for RARC and ORC.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 7.3.6 Urinary diversion after radical cystectomy

From an anatomical standpoint, three alternatives are currently used after cystectomy:

- abdominal diversion, such as an uretero-cutaneostomy, ileal or colonic conduit, and various forms of a continent pouch (infrequently used);
- urethral diversion, which includes various forms of gastrointestinal pouches attached to the urethra as a continent, orthotopic urinary diversion (neobladder, orthotopic bladder substitution);
- rectosigmoid diversions, such as uretero-(ileo-)rectostomy (infrequently used).

Different types of segments of the intestinal tract have been used to reconstruct the urinary tract, including the stomach, ileum, colon and appendix [350]. Several studies have compared certain aspects of health-related quality of life (HRQoL) such as sexual function, urinary continence and body image in patient cohorts with different types of urinary diversion [351]. However, further research evaluating the impact of pre-operative tumour stage, functional- and socio-economic status, and time interval to primary surgery are needed.

#### 7.3.6.1 Patient selection and preparations for surgery

In consultation with the patient, both an orthotopic neobladder and ileal conduit should be considered in case reconstructive surgery exposes the patient to excessive risk (as determined by comorbidity and age).

Ensuring that patients make a well-informed decision about the type of urinary diversion is associated with less decision regret post-operatively, independent of the method selected [352].

Diagnosis of an invasive urethral tumour prior to cystectomy leads to urethrectomy which could be a contraindication for a neobladder reconstruction. If indicated; in males, in case of CIS and extension of tumour in the prostatic urethra, urethral frozen section has to be performed on the cystoprostatectomy specimen just under the verumontanum and on the inferior limits of the bladder neck; in females a urethral frozen section has to be taken just below the bladder neck.

Non-muscle-invasive BC in prostatic urethra or bladder neck biopsies does not necessarily preclude orthotopic neobladder substitution, provided that patients undergo regular follow-up cystoscopy and urinary cytology [353].

In the presence of positive LNs, orthotopic neobladder can nevertheless be considered in case of N1 involvement (metastasis in a single node in the true pelvis) but not in N2 or N3 tumours [354].

Oncological results after orthotopic neobladder substitution or conduit diversion are similar in terms of local or distant metastasis recurrence, but secondary urethral tumours seem less common in patients with a neobladder compared to those with conduits or continent cutaneous diversions [355].

For cystectomy, general preparations are necessary as for any other major pelvic and abdominal surgery. If the urinary diversion is constructed from gastrointestinal segments, the length or size of the respective segments and their pathophysiology when storing urine must be considered [356]. Despite the necessary interruption and re-anastomosis of the bowel, formal bowel preparation may not be necessary [357]. Bowel recovery time can be reduced by the use of early mobilisation and early oralsation, gastrointestinal stimulation with metoclopramide and chewing gum [358]. Patients treated according to the “fast tract”/ERAS (Early Recovery After Surgery) protocol have shown to score better on the emotional and physical functioning scores and suffer less from wound healing disorders, fever and thrombosis [359].
A cornerstone of the ERAS protocol is post-operative pain management, which involves significantly reducing the use of opioids; offering opioids mainly as breakthrough pain medication. Instead of patient-controlled analgesia and epidural opioids, most patients receive high-dose acetaminophen and/or ketorolac, starting intra-operatively. Patients on ERAS experience more pain as compared to patients on a traditional protocol (Visual Analogue Scale 3.1 vs. 1.1, \( p < 0.001 \)), but post-operative ileus decreased from 22\% to 7.3\% \( (p = 0.003) \) [360].

A multicentre randomised placebo-controlled trial showed that patients receiving alvimopan, a peripherally acting μ-opioid receptor antagonist, had quicker bowel recovery compared to patients receiving placebo [361]. However, this drug is, as yet, not approved in Europe.

Venous thromboembolism (VTE) prophylaxis may be implemented as part of an ERAS protocol. A single-centre non-randomised study showed a significant lower 30-day VTE incidence rate in patients treated for 28 days with enoxaparin compared to patients without prophylaxis [362]. Data from the Ontario Cancer Registry including 4,205 cystectomy patients of whom 1,084 received NAC showed that VTE rates are higher in patients treated with NAC as compared to patients treated with cystectomy only (12\% vs. 8\%, \( p = 0.002 \)) [363, 364].

Patients undergoing continent urinary diversion must be motivated to learn about their diversion and to be manually skilful in manipulating their diversion. Contraindications to more complex forms of urinary diversion include:

- debilitating neurological and psychiatric illnesses;
- limited life expectancy;
- impaired liver or renal function;
- urothelial carcinoma positive surgical margins.

Relative contraindications specific for an orthotopic neobladder are high-dose pre-operative RT, complex urethral stricture disease and severe urethral sphincter-related incontinence [365].

7.3.6.2 Different types of urinary diversion

Radical cystectomy and urinary diversion are the two steps of one operation. However, the literature uniformly reports complications of RC while ignoring the fact that most complications are diversion related [366]. Age alone is not a criterion for offering continent diversion [365, 367]. Comorbidity, cardiac- and pulmonary function and cognitive function are all important factors that should be considered, along with the patient’s social support and preference.

Age > 80 years is often considered to be the threshold after which neobladder reconstruction is not recommended. However, there is no exact age for a strict contraindication. In most large series from experienced centres, the rate of orthotopic bladder substitution after cystectomy for bladder tumour is up to 80\% in men and 50\% in women [368-371]. Nevertheless, no RCTs comparing conduit diversion with neobladder or continent cutaneous diversion have been performed.

A retrospective study including 1,383 patients showed that the risk of a decline in estimated glomerular filtration rate (eGFR) did not significantly differ after ileal conduit vs. neobladder in patients with pre-operative chronic kidney disease 2 (eGFR 60–89 mL/min/1.73 m²) or 3a (eGFR 45–59 mL/min/1.73 m²) [372]. Only age and anastomotic strictures were found to be associated with a decline in eGFR.

7.3.6.2.1 Uretero-cutaneostomy

Ureteral diversion to the abdominal wall is the simplest form of cutaneous diversion. Operating time, complication rate, stay at intensive care and length of hospital stay are lower in patients treated with uretero-cutaneostomy as compared to ileal conduit [373]. Therefore, in frail patients and/or in those with a solitary kidney who need a supravesical diversion, uretero-cutaneostomy is the preferred procedure [374, 375]. Quality of life, which was assessed using the Bladder Cancer Index (BCI), showed equal urinary bother and function for patients treated with ileal conduit and uretero-cutaneostomy [373]. However, others have demonstrated that in carefully selected elderly patients, all other forms of wet and dry urinary diversions, including orthotopic bladder substitutions, are possible [376].

Technically, in case patients have both kidneys; either one ureter, to which the other shorter one is attached end-to-side, is connected to the skin (trans-uretero-cutaneostomy) or both ureters are directly anastomosed to the abdominal wall creating a stoma. Due to the smaller diameter of the ureters, stoma stenosis has been observed more frequently for this technique as compared to using small or large bowel to create an intestinal stoma [374].

In a retrospective multicentre study peri-operative morbidity was evaluated for urinary diversion using bowel as compared to uretero-cutaneostomy. Patients selected for a uretero-cutaneostomy were older and had a higher ASA score, while their mean Charlson score was lower (4.2 vs. 5.6, \( p < 0.001 \)) [377].
Despite the limited comparative data available, it must be taken into consideration that older data and clinical experience suggest ureter stenosis at the skin level and ascending UTI are more frequent complications in uretero-cutaneostomy compared to an ileal conduit diversion. In a retrospective study comparing various forms of intestinal diversion, ileal conduits had fewer late complications than continent abdominal pouches or orthotopic neobladders [378].

### 7.3.6.2.2 Ileal conduit

The ileal conduit is still an established option with well-known/predictable results. However, up to 48% of patients develop early complications including UTIs, pyelonephritis, ureteroileal leakage and stenosis [378]. The main complications in long-term follow-up studies are stomal complications in up to 24% of patients and functional and/or morphological changes of the UUT in up to 30% [378-380]. An increase in complications was seen with longer follow-up in the Berne series of 131 patients who were followed for a minimum of five years (median follow-up 98 months) [381]; the rate of complications increased from 45% at five years to 94% in those surviving > 15 years. In the latter group, 50% of patients developed UUT changes and 38% developed urolithiasis.

### 7.3.6.2.3 Orthotopic neobladder

An orthotopic bladder substitution to the urethra is now commonly used both in men and women. Contemporary reports document the safety and long-term reliability of this procedure. In several large centres, this has become the diversion of choice for most patients undergoing cystectomy [213, 273, 365]. However, in elderly patients (> 80 years) it is rarely performed even in high-volume expert centres [382, 383].

The terminal ileum is the gastrointestinal segment most often used for bladder substitution. There is less experience with the ascending colon, including the caecum, and the sigmoid [273]. Emptying of the reservoir anastomosed to the urethra requires abdominal straining, intestinal peristalsis, and sphincter relaxation. Early and late morbidity in up to 22% of patients is reported [384, 385]. In two studies of 1,054 and 1,300 patients [365, 386], long-term complications included diurnal (8–10%) and nocturnal (20–30%) incontinence, uretero-intestinal stenosis (3–18%), metabolic disorders, and vitamin B12 deficiency. A study comparing cancer control and patterns of disease recurrence in patients with neobladder and ileal conduit showed no difference in CSS between the two groups when adjusting for pathological stage [387]. Urethral recurrence in neobladder patients seems rare (1.5–7% in both male and female patients) [365, 388]. These results indicate that neobladder in male and female patients does not compromise the oncological outcome of cystectomy. It remains debatable whether patient’s QoL for neobladder is better compared to non-continent urinary diversion [389, 390].

Continent cutaneous urinary diversion (a low-pressure detubularised ileal reservoir for self-catheterisation) and uretero-rectosigmoidostomy are rarely used techniques nowadays, due to their high complication rates, including stomal stenosis, incontinence in the continent cutaneous diversion, UUT infections and stone formation in case of uretero-rectosigmoidostomy [391].

Various forms of UUT reflux protection, including a simple isoperistaltic tunnel, ileal intussusception, tapered ileal prolongation implanted subserosally, and direct (sub)mucosal or subserosal ureteral implantation, have been described [385, 392]. According to the long-term results, the UUT is protected sufficiently by either method.

A detailed investigation of the bladder neck prior to RC is important for women who are scheduled for an orthotopic bladder substitute [393]. In women undergoing RC the rate of concomitant urethral malignancy has been reported to range from 12–16% [394]. Localisation of the primary tumour at the bladder neck correlated strongly with concomitant urethral malignancy. In addition, tumour involving the bladder neck and urethra tended to be associated with a higher risk of advanced stage and nodal involvement [395].

Currently, it is not possible to recommend a particular type of urinary diversion. However, most institutions prefer ileal orthotopic neobladders and ileal conduits based on clinical experience [396, 397]. In selected patients, such as patients with a single kidney, uretero-cutaneostomy is surgically the least burdensome type of diversion. Recommendations related to RC and urinary diversions are listed in Section 7.3.10.

### 7.3.7 Morbidity and mortality

In three long-term studies and one population-based cohort study, the peri-operative mortality was reported as 1.2–3.2% at 30 days and 2.3–8.0% at 90 days [213, 366, 368, 398, 399]. In a large single-centre series early complications (within three months of surgery) were seen in 58% of patients [366]. Late morbidity was usually linked to the type of urinary diversion (see also above) [369, 400]. Early morbidity associated with RC
for NMIBC (at high risk for disease progression) is similar and no less than that associated with muscle-invasive tumours [401]. In general, lower morbidity and (peri-operative) mortality have been observed by surgeons and in hospitals with a higher case load and therefore more experience [398, 402-406].

**Table 7.6: Management of neobladder morbidity** (30-64%) [407]

<table>
<thead>
<tr>
<th>CLAVIEN System</th>
<th>Morbidity</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade I</strong></td>
<td>Any deviation from the normal post-operative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs such as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside.</td>
<td>Immediate complications:</td>
</tr>
<tr>
<td></td>
<td>Post-operative ileus</td>
<td>Nasogastric intubation (usually removed at day 1) Chewing gum Avoid fluid excess and hypovolemia (provoke splanchnic hypoperfusion)</td>
</tr>
<tr>
<td></td>
<td>Post-operative nausea and vomiting</td>
<td>Antiemetic agent (decrease opioids) Nasogastric intubation</td>
</tr>
<tr>
<td></td>
<td>Urinary infection</td>
<td>Antibiotics, no ureteral catheter removal Check the 3 drainages (ureters and neobladder)</td>
</tr>
<tr>
<td></td>
<td>Ureteral catheter obstruction</td>
<td>Inject 5 cc saline in the ureteral catheter to resolve the obstruction Increase volume infusion to increase diuresis</td>
</tr>
<tr>
<td></td>
<td>Intra-abdominal urine leakage (anastomosis leakage)</td>
<td>Check drainages and watchful waiting</td>
</tr>
<tr>
<td></td>
<td>Anaemia well tolerated</td>
<td>Martial treatment (give iron supplement)</td>
</tr>
<tr>
<td><strong>Late complications:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non compressive lymphocele</td>
<td>Watchful waiting</td>
</tr>
<tr>
<td></td>
<td>Mucus cork</td>
<td>Cough Indwelling catheter to remove the obstruction</td>
</tr>
<tr>
<td></td>
<td>Incontinence</td>
<td>Urine analysis (infection), echography (post-void residual) Physiotherapy</td>
</tr>
<tr>
<td></td>
<td>Retention</td>
<td>Drainage and self-catheterisation education</td>
</tr>
<tr>
<td><strong>Grade II</strong></td>
<td>Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.</td>
<td>Anaemia badly tolerated or if myocardial cardiopathy history</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transfusion(^1)(^2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pyelonephritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Confusion or neurological disorder</td>
</tr>
<tr>
<td><strong>Grade III</strong></td>
<td>Requiring surgical, endoscopic or radiological intervention</td>
<td>Ureteral catheter accidentally dislodged</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indwelling leader to raise the ureteral catheter</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anastomosis stenosis (7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ureteral reflux</td>
</tr>
</tbody>
</table>
### III-a
- Intervention not under general anaesthesia
- Compressive lymphocele
- Transcutaneous drainage or intra-operative marsupialisation (cf grade III)

### III-b
- Intervention under general anaesthesia
- Ileal anastomosis leakage
- Ileostomy, as soon as possible
- Evisceration
- Surgery in emergency
- Compressive lymphocele
- Surgery (marsupialisation)

### Grade IV
- Life-threatening complication (including central nervous system complications: brain haemorrhage, ischaemic stroke, subarachnoid bleeding, but excluding transient ischaemic attacks) requiring intensive care/ intensive care unit management.
- Rectal necrosis
- Colostomy
- Neobladder rupture
- Nephrostomy and indwelling catheter/surgery for repairing neobladder
- Severe sepsis
- Antibiotics and check all the urinary drainages and CT scan in emergency

### IV-a
- Single organ dysfunction (including dialysis)
- Non-obstructive renal failure
- Bicarbonate/aetiology treatment

### IV-b
- Multi-organ dysfunction
- Obstructive pyelonephritis and sepsicaemia
- Nephrostomy and antibiotics

### Grade V
- Death of a patient

**Suffix “d”**
If the patient suffers from a complication at the time of discharge, the suffix “d” (for “disability”) is added to the respective grade of complication. This label indicates the need for a follow-up to fully evaluate the complication.

1. A systematic review showed that peri-operative blood transfusion (PBT) in patients who undergo RC correlates with increased overall mortality, CSM and cancer recurrence. The authors hypothesised that this may be caused by the suggested immunosuppressive effect of PBT. The foreign antigens in transfused blood induce immune suppression, which may lead to tumour cell spread, tumour growth and reduced survival in already immunosuppressed cancer patients. As other possible causes for this finding increased post-operative infections and blood incompatibility were mentioned [408]. Buchner and co-workers showed similar results in a retrospective study. The 5-year CSS decreased in cases where intra-operative blood transfusion (CSS decreased from 67% to 48%) or post-operative blood transfusion (CSS decreased from 63% to 48%) were given [409].

2. Intra-operative tranexamin acid infusion reduces peri-operative blood transfusion rates from 57.7% to 31.1%. There was no increase seen in peri-operative VTE [410].

3. Hammond and co-workers reviewed 20,762 cases of VTE after major surgery and found cystectomy patients to have the second highest rate of VTE among all cancers studied [411]. These patients benefit from 30 days low-molecular-weight heparin prophylaxis. Subsequently, it was demonstrated that BMI > 30 and non-urothelial BCs are independently associated with VTE after cystectomy. In these patients extended (90 days) heparin prophylaxis should be considered [412].

#### 7.3.8 Survival
According to a multi-institutional database of 888 consecutive patients undergoing RC for BC, the 5-year RFS rate was 58% and CSS was 66% [413]. External validation of post-operative nomograms for BC-specific mortality showed similar results, with bladder-CSS of 62% [414].

Recurrence-free survival and OS in a large single-centre study of 1,054 patients was 68% and 66% at five years and 60% and 43%, at ten years, respectively [212]. However, the 5-year RFS in node-positive patients who underwent cystectomy was considerably less at 34–43% [415, 416]. In a surgery-only study, the 5-year RFS was 76% in patients with pT1 tumours, 74% for pT2, 52% for pT3, and 36% for pT4 [212].

A trend analysis based on 148,315 BC patients identified in the SEER database between 1973 and 2009 showed increased stage-specific 5-year survival rates for all stages, except for metastatic disease [417].

#### 7.3.9 Impact of hospital and surgeon volume on treatment outcomes
Recently, a systemic review was performed to assess the impact of hospital and/or surgeon volume on peri-operative outcomes of RC [418]. In total, 40 studies including over 560,000 patients were included. All studies were retrospective cohort studies.
Twenty-two studies reported on hospital volume only, six studies on surgeon volume only and twelve studies reported on both. The results of this systematic review suggest that a higher hospital volume is likely associated with lower in-hospital, 30-day and 90-day mortality rates. Also, higher volume hospitals are likely to have lower positive surgical margins, higher LND and neobladder rates and lower complication rates. For surgeon volume, less evidence is available and it seems that outcome after RC is mainly hospital-driven. In spite of the lower quality, the available evidence suggests that performing more than 10 RCs per year per hospital reduces 30- and 90-day mortality. Performing more than 20 RCs per hospital per year might even further reduce these mortality rates.

### 7.3.10 Summary of evidence and guidelines for radical cystectomy and urinary diversion

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensuring that patients are well informed about the various urinary diversion options prior to making a decision may help prevent or reduce decision regret, independent of the method of diversion selected.</td>
<td>3</td>
</tr>
<tr>
<td>Higher hospital volume likely improves quality of care and reduction in peri-operative mortality and morbidity.</td>
<td>3</td>
</tr>
<tr>
<td>Radical cystectomy includes removal of regional lymph nodes.</td>
<td>3</td>
</tr>
<tr>
<td>There are data to support that extended lymph node dissection (LND) (vs. standard or limited LND) improves survival after RC.</td>
<td>3</td>
</tr>
<tr>
<td>Radical cystectomy in both sexes must not include removal of the entire urethra in all cases, which may then serve as the outlet for an orthotopic bladder substitution. The terminal ileum and colon are the intestinal segments of choice for urinary diversion.</td>
<td>3</td>
</tr>
<tr>
<td>The type of urinary diversion does not affect oncological outcome.</td>
<td>3</td>
</tr>
<tr>
<td>The use of extended venous thromboembolism (VTE) prophylaxis significantly decreases the incidence of VTE after RC.</td>
<td>3</td>
</tr>
<tr>
<td>In patients aged &gt; 80 years with MIBC, cystectomy is an option.</td>
<td>3</td>
</tr>
<tr>
<td>Surgical outcome is influenced by comorbidity, age, previous treatment for bladder cancer or other pelvic diseases, surgeon and hospital volumes of cystectomy, and type of urinary diversion.</td>
<td>2</td>
</tr>
<tr>
<td>Surgical complications of cystectomy and urinary diversion should be reported using a uniform grading system. Currently, the best-adapted grading system for cystectomy is the Clavien grading system.</td>
<td>2</td>
</tr>
<tr>
<td>No conclusive evidence exists as to the optimal extent of LND.</td>
<td>2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not delay radical cystectomy (RC) for &gt; 3 months as it increases the risk of progression and cancer-specific mortality, unless the patient receives neo-adjuvant chemotherapy.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform at least 10, and preferably &gt; 20, RCs per hospital/per year.</td>
<td>Strong</td>
</tr>
<tr>
<td>Before RC, fully inform the patient about the benefits and potential risks of all possible alternatives. The final decision should be based on a balanced discussion between the patient and the surgeon.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not offer an orthotopic bladder substitute diversion to patients who have a tumour in the urethra or at the level of urethral dissection.</td>
<td>Strong</td>
</tr>
<tr>
<td>Pre-operative bowel preparation is not mandatory. “Fast track” measurements may reduce the time to bowel recovery.</td>
<td>Strong</td>
</tr>
<tr>
<td>Offer pharmacological prophylaxis, such as low-molecular-weight heparin to RC patients, starting the first day post-surgery, for a period of 4 weeks.</td>
<td>Strong</td>
</tr>
<tr>
<td>Offer RC to patients with T2–T4a, N0M0 disease or high-risk non-muscle-invasive bladder cancer.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform a lymph node dissection as an integral part of RC.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not preserve the urethra if margins are positive.</td>
<td>Strong</td>
</tr>
</tbody>
</table>
7.3.11 **EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer** [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidates for curative treatment, such as cystectomy or bladder preservation, should be clinically assessed by at least an oncologist, a urologist, a radiation oncologist (in case adjuvant radiotherapy or bladder preservation is considered) and a neutral healthcare professional such as a specialist nurse.</td>
</tr>
<tr>
<td>Muscle-invasive pure squamous cell carcinoma of the bladder should be treated with primary radical cystectomy and lymphadenectomy.</td>
</tr>
<tr>
<td>Muscle-invasive pure adenocarcinoma of the bladder should be treated with primary radical cystectomy and lymphadenectomy.</td>
</tr>
<tr>
<td>T1 high-grade bladder urothelial cancer with micropapillary histology (established after complete TURBT and/or re-TURBT) should be treated with immediate radical cystectomy and lymphadenectomy.</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa). TURBT = transurethral resection of bladder tumour.

**Figure 7.1: Flow chart for the management of T2–T4a N0M0 urothelial bladder cancer**

- **Diagnosis**
  - Cystoscopy and tumour resection
  - Evaluation of urethra
  - CT imaging of abdomen, chest, UUT
  - MRI can be used for local staging

- **Findings**
  - cT2-4N0M0

- **Neo-adjuvant therapy**
  - **Chemotherapy**
    - Recommended in cisplatin-fit patients (5-8% survival benefit)
  - **Radiotherapy**
    - Not recommended
  - **Immunotherapy**
    - Experimental, only in clinical trial setting

- **Radical cystectomy**
  - **Know general aspects of surgery**
    - Preparation
    - Surgical technique
    - Integrated node dissection
    - Urinary diversion
    - Timing of surgery
  - **A higher case load improves outcome**

- **Adjuvant chemotherapy**
  - **Consider in high-risk patients only if no neo-adjuvant therapy was given**

CT = computed tomography; MRI = magnetic resonance imaging; UUT = upper urinary tract.
7.4 Unresectable tumours

7.4.1 Palliative cystectomy for muscle-invasive bladder carcinoma

Locally advanced tumours (T4b, invading the pelvic or abdominal wall) may be accompanied by several debilitating symptoms, including bleeding, pain, dysuria and urinary obstruction. These patients are candidates for palliative treatments, such as palliative RT. Palliative cystectomy with urinary diversion carries the greatest morbidity and should be considered for symptom relief only if there are no other options [419-421].

Locally advanced MIBC can be associated with ureteral obstruction due to a combination of mechanical blockade by the tumour and invasion of ureteral orifices by tumour cells. In a series of 61 patients with obstructive uraemia RC was not an option in 23 patients and obstruction was relieved using permanent nephrostomy tubes [422]. Another ten patients underwent palliative cystectomy, but local pelvic recurrence occurred in all ten patients within the first year of follow-up. Another small study (n = 20) showed that primary cystectomy for T4 BC was technically feasible and associated with a very tolerable therapy-related morbidity and mortality [423].

7.4.1.1 Guidelines for unresectable tumours

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer radical cystectomy as a palliative treatment to patients with inoperable locally advanced tumours (T4b).</td>
<td>Weak</td>
</tr>
<tr>
<td>Offer palliative cystectomy to patients with symptoms.</td>
<td>Weak</td>
</tr>
</tbody>
</table>

7.4.1.2 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with clinical T4 or clinical N+ disease (regional), radical chemoradiation can be offered accepting that this may be palliative rather than curative in outcome.</td>
</tr>
<tr>
<td>Chemoradiation should be given to improve local control in cases of inoperable locally advanced tumours.</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

7.4.2 Supportive care

7.4.2.1 Obstruction of the upper urinary tract

Unilateral (best kidney) or bilateral nephrostomy tubes provide the easiest solution for UUT obstruction, but patients find the tubes inconvenient and prefer ureteral stenting. However, stenting can be difficult to achieve. Stents must be regularly replaced and there is the risk of stent obstruction or displacement. Another possible solution is a urinary diversion with, or without, a palliative cystectomy.

7.4.2.2 Bleeding and pain

In the case of bleeding, the patient must be screened first for coagulation disorders or the patient’s use of anticoagulant drugs must be reviewed. Transurethral (laser) coagulation may be difficult in a bladder full of tumour or with a bleeding tumour. Intravesical rinsing of the bladder with 1% silver nitrate or 1–2% alum can be effective [424]. This can usually be done without any anaesthesia. The instillation of formalin (2.5–4% for 30 minutes) is a more aggressive and painful procedure, requiring anaesthesia. Formalin instillation has a higher risk of side-effects, e.g., bladder fibrosis, but is more likely to control the bleeding [424]. Vesicoureteral reflux should be excluded to prevent renal complications.

Radiation therapy is another common strategy to control bleeding and is also used to control pain. An older study reported control of haematuria in 59% of patients and pain control in 73% [425]. Irritative bladder and bowel complaints due to irradiation are possible, but are usually mild. Non-conservative options are embolisation of specific arteries in the small pelvis, with success rates as high as 90% [424]. Radical surgery is a last resort and includes cystectomy and diversion (see above, Section 7.4.1).

7.5 Bladder-sparing treatments for localised disease

7.5.1 Transurethral resection of bladder tumour

Transurethral resection of bladder tumour alone in MIBC patients is only possible as a therapeutic option if tumour growth is limited to the superficial muscle layer and if re-staging biopsies are negative for residual (invasive) tumour [426]. In general, approximately 50% of patients will still have to undergo RC for recurrent
MIBC with a disease-specific mortality rate of up to 47% within this group [427]. A disease-free status at re-staging TURB appears to be crucial in making the decision not to perform RC [428, 429]. A prospective study by Solsona et al., including 133 patients with radical TURB and re-staging negative biopsies, reported a 15-year follow-up [429]. Thirty per cent of patients had recurrent NMIBC and went on to intravesical therapy, and 30% (n = 40) progressed, of which 27 died of BC. After five, ten, and fifteen years, the results showed CSS rates of 81.9%, 79.5%, and 76.7%, respectively and PFS rates with an intact bladder of 75.5%, 64.9%, and 57.8%, respectively.

In conclusion, TURB alone should only be considered as a therapeutic option for muscle-invasive disease after radical TURB, when the patient is unfit for cystectomy, or refuses open surgery, or as part of a multimodality bladder-preserving approach.

7.5.1.1 Guideline for transurethral resection of bladder tumour

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer transurethral resection of bladder tumour alone as a curative treatment option as most patients will not benefit.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

7.5.1.2 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidates for curative treatment, such as cystectomy or bladder preservation, should be clinically assessed by at least an oncologist, a urologist, a radiation oncologist (in case adjuvant radiotherapy or bladder preservation is considered) and a neutral HCP such as a specialist nurse.</td>
</tr>
<tr>
<td>An important determinant for patient eligibility in case of bladder-preserving treatment is absence of carcinoma in situ.</td>
</tr>
<tr>
<td>An important determinant for patient eligibility in case of bladder-preserving treatment is absence or presence of hydronephrosis.</td>
</tr>
<tr>
<td>When assessing patient eligibility for bladder preservation, the likelihood of successful debulking surgery should be taken into consideration (optimal debulking).</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa). HCP = healthcare professional.

7.5.2 External beam radiotherapy

Current RT techniques with soft-tissue matching and image guidance result in superior bladder coverage and a reduced integral dose to the surrounding tissues. The target total dose (to bladder and/or bladder tumour) for curative EBRT in BC is 64–66 Gy [430, 431]. A reasonable alternative is moderately hypofractionated EBRT to 55 Gy in 20 fractions which has been suggested to be non-inferior to 64 Gy in 32 fractions in terms of invasive locoregional control, OS, and late toxicity. In a phase II study, 55 patients (median age 86) with BC, unfit for cystectomy or even daily RT, were treated with 6-weekly doses of 6 Gy [432]. Forty-eight patients completed EBRT with acceptable toxicity and 17% showed local progression after two years demonstrating good local control with this more ultra-hypofractionated schedule.

Elective treatment to the LNs is optional and should take into account patient comorbidities and the risks of toxicity to adjacent critical structures. For node-positive disease, consider boosting grossly involved nodes to the highest achievable dose that does not violate normal tissue constraints based on the clinical scenario.

The use of modern standard EBRT techniques results in major related late morbidity of the urinary bladder or bowel in less than 5% of patients [433]. Acute diarrhoea is reduced even more with intensity-modulated RT [434]. Important prognostic factors for outcome include response to EBRT, tumour size, hydronephrosis, presence of CIS, and completeness of the initial TURB. Additional prognostic factors reported are age and stage [435].

With the use of modern EBRT techniques, efficacy and safely results seem to have improved over time. A 2002 Cochrane analysis demonstrated that RC has an OS benefit compared to RT [436], although this was not the case in a 2014 retrospective review using a propensity score analysis [437]. In a 2017 retrospective cohort study of U.S. National Cancer Data Base data, patients over 80 were identified with cT2–4, N0–3, M0 BC, who were treated with curative EBRT (60–70 Gy, n = 739) or concurrent chemoradiotherapy (n = 630) between 2004 and 2013 [438]. The 2-year OS was 42% for EBRT vs. 56% for chemoradiotherapy (p < 0.001). For EBRT a higher RT dose and a low stage were associated with improved OS.
In conclusion, although EBRT results seem to improve over time, EBRT alone does not seem to be as effective as surgery or trimodality therapy (see Section 7.5.4). Factors that influence outcome should be considered. However, EBRT can be an alternative treatment in patients unfit for radical surgery or concurrent chemotherapy, and it can also be quite effective in helping control bleeding.

7.5.2.1 Summary of evidence and guideline for external beam radiotherapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>External beam radiotherapy alone should only be considered as a therapeutic option when the patient is unfit for cystectomy.</td>
<td>3</td>
</tr>
<tr>
<td>Radiotherapy can also be used to stop bleeding from the tumour when local control cannot be achieved by transurethral manipulation because of extensive local tumour growth.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer radiotherapy alone as primary therapy for localised bladder cancer.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

7.5.2.2 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [8, 9]*

<table>
<thead>
<tr>
<th>Consensus statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy alone (single block) is not the preferred radiotherapeutic schedule.</td>
</tr>
<tr>
<td>Radiotherapy for bladder preservation should be performed with IMRT and IGRT to reduce side effects.</td>
</tr>
<tr>
<td>Dose escalation above standard radical doses to the primary site in case of bladder preservation, either by IMRT or brachytherapy, is not recommended.</td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

IGRT = image-guided radiotherapy; IMRT = intensity-modulated radiotherapy.

7.5.3 Chemotherapy

Chemotherapy alone rarely produces durable complete remissions. In general, a clinical complete response rate of up to 56% is reported in some series, which must be weighed against a staging error of > 60% [439, 440]. Response to chemotherapy is a prognostic factor for treatment outcome and eventual survival although it may be confounded by patient selection [441].

Several groups have reported the effect of chemotherapy on resectable tumours (neoadjuvant approach), as well as unresectable primary tumours [223, 240, 442, 443]. Neoadjuvant chemotherapy with two to three cycles of MVAC or CMV has led to a down-staging of the primary tumour in various prospective series [223, 240, 442].

A bladder-conserving strategy with TURB and systemic cisplatin-based chemotherapy has been reported several years ago and could lead to long-term survival with intact bladder in a highly selected patient population [441].

A recent large retrospective analysis of a National Cancer Database cohort reported on 1,538 patients treated with TURB and multi-agent chemotherapy [444]. The two and 5-year OS for all patients was 49% and 32.9% and for cT2 patients it was 52.6% and 36.2%, respectively. While these data show that long-term survival with intact bladder can be achieved in a subset of patients it is not recommended for routine use.

7.5.3.1 Summary of evidence and guideline for chemotherapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete and partial local responses have been reported with cisplatin-based chemotherapy as primary therapy for locally advanced tumours in highly selected patients.</td>
<td>2b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not offer chemotherapy alone as primary therapy for localised bladder cancer.</td>
<td>Strong</td>
</tr>
</tbody>
</table>
Trimodality bladder-preserving treatment

Trimodality therapy (TMT) combines TURB, chemotherapy and RT. The rationale to combine TURB with RT is to maximally achieve local tumour control in the bladder and adjacent nodes. The addition of radiosensitising chemotherapy or other radiosensitisers (mentioned below) is aimed at the potentiation of RT. Micrometastases are targeted by platinum-based combination chemotherapy (for details see Section 7.1). The aim of TMT is to preserve the bladder and QoL without compromising oncological outcome.

There are no successfully completed RCTs comparing the outcome of TMT with RC, but TMT using chemoradiation has been shown to be superior to RT alone [445, 446]. Many of the reported series have differing characteristics as compared to the larger surgical series, which typically have median ages in the mid-to-late 60s compared to mid-70s for some large RT series (reviewed by James, et al. [445]). In the case of TMT, two distinct patterns of care emerge; treatment aimed at patients fit for cystectomy who elect TMT or refuse cystectomy, and treatment aimed at older, less fit, patients. For the former category, TMT presents selective bladder preservation and in this case the initial step is a radical TURB where as much tumour as possible should be resected. In this case appropriate patient selection (e.g., T2 tumours, no CIS) is critical [447, 448]. Even in case of an initial presumed complete resection, a second TUR has been suggested to reveal tumour in > 50% of patients and subsequently improves 5-year OS in case of TMT [449]. For patients who are not candidates for cystectomy, less stringent criteria can be applied, but extensive CIS and poor bladder function should both be regarded as relative contraindications.

A collaborative review has described the principles of TMT [450]. For radiation, two schedules are most commonly used; historically within the RTOG a split-course format with interval cystoscopy [448] and single-phase treatment which is now more commonly used [445]. A conventional radiation schedule includes EBRT to the bladder and limited pelvic LNs with an initial dose of 40-45 Gy, with a boost to the whole bladder of 50–54 Gy and a further tumour boost to a total dose of 60–66 Gy. If not boosting the tumour, it is also reasonable for the whole bladder to be treated to 59.4–66 Gy. For node-positive disease, consider boosting grossly involved nodes to the highest achievable dose that does not violate normal tissue constraints. Therefore, elective treatment to the LNs (when node negative) is optional and should take into account patient comorbidities and the risks of toxicity to adjacent critical structures.

In summary, reasonable radiation fields include pelvis (with bladder and/or bladder tumour boost), bladder only or partial bladder (tumour) only [445]. A reasonable radiation dosing alternative to conventional fractionation when treating the bladder-only fields is moderately hypofractionated EBRT to 55 Gy in 20 fractions which has been suggested to be non-inferior to 64 Gy in 32 fractions (fx) in terms of invasive loco-regional control, OS and late toxicity [430, 451].

Different chemotherapy regimens have been used, but most evidence exists for cisplatin [452] and mitomycin C plus 5-FU [445]. In addition to these agents, other regimens have also been used such as gemcitabine and hypoxic cell sensitisation with nicotinamide and carbogen, without clear preference for a specific radiosensitiser [8, 9]. In a recently published phase II RCT, twice-a-day radiation plus fluorouracil/cisplatin was compared to once-daily radiation plus gemcitabine [453]. Both arms were found to result in a > 75% freedom of distant metastases at 3 years (78% and 84%, respectively). Therefore, there are options for non-cisplatin candidates such as 5-FU/mitomycin C or low-dose gemcitabine.

To detect non-responders who should be offered salvage cystectomy, bladder biopsies should be performed after TMT and life-long cystoscopic surveillance is recommended.

Five-year CSS and OS rates vary between 50%–84% and 36%–74%, respectively, with salvage cystectomy rates of 10–30% [445, 447, 450, 452, 454, 455]. The Boston group reported on their experience in 66 patients with mixed variant histologies treated with TMT and found similar complete response, OS, DSS and salvage cystectomy rates as in UC [456]. The majority of recurrences post-TMT are non-invasive and can be managed conservatively [445]. In contemporary experiences, salvage cystectomy is required in about 10–15% of patients treated with TMT and can be curative [445, 447, 455]. Current data suggest that major late complication rates are slightly higher but remain acceptable for salvage- vs. primary cystectomy [457, 458].

A sub-analysis of two RTOG trials looked at complete response (T0) and near-complete response (Ta or Tis) after TMT [459]. After a median follow-up of 5.9 years 41/119 (35%) of patients experienced a bladder recurrence, and fourteen required salvage cystectomy. There was no difference between complete and near-complete responders. Non-muscle-invasive BC recurrences after complete response to TMT were reported in 25% of patients by the Boston group, sometimes over a decade after initial treatment [460]. A NMIBC
recurrence was associated with a lower DSS, although in properly selected patients, intravesical BCG could avoid immediate salvage cystectomy.

The differential impact of RC vs. TMT on long-term OS is lacking a randomised comparison and rigorous prospective data. A propensity score matched institutional analysis has suggested similar DSS and OS between TMT and RC [455]. Two retrospective analyses of the National Cancer Database from 2004–2013 with propensity score matching compared RC to TMT. Ritch et al. identified 6,606 RC and 1,773 TMT patients [461]. Worse survival was linked to higher age, comorbidity and tumour stage. After modelling, TMT resulted in a lower mortality at one year (HR: 0.84, 95% CI: 0.74–0.96, p = 0.01). However, in years 2 and onwards, there was a significant and persistent higher mortality after TMT (year 2: HR: 1.4, 95% CI: 1.2–1.6, p < 0.001; and year 3 onwards: HR: 1.5, 95% CI: 1.2–1.8, p < 0.001). The second analysis was based on a larger cohort, with 22,680 patients undergoing RC; 2,540 patients received definitive EBRT and 1,489 TMT [462]. Survival after modelling was significantly better for RC compared to any EBRT, definitive EBRT and TMT (HR: 1.4, 95% CI: 1.2–1.6) at any time point. In older patients which are potentially less ideal candidates for radical surgery, Williams et al. found a significantly lower OS (HR :1.49, 1.31–1.69) and CSS (1.55, 1.32–1.83) for TMT as compared to surgery as well as increased costs [463]. This was a retrospective SEER database study which included 687 propensity-matched patients in each arm, however, the median number of radiation fractions was well below what is considered adequate for definitive therapy and as such the radiation patients may have been treated inadequately or palliatively. In general, such population-based studies are limited by confounding, misclassification, and selection bias. A systematic review including 57 studies and over 30,000 patients comparing RC and TMT found improved 10-year OS and DSS for TMT, but for the entire cohort OS and DSS did not significantly differ between RC and TMT [464]. Complete response after TMT resulted in significantly better survival, as did down-staging after TURB or NAC in case of RC.

Overall significant late pelvic (GI/genitourinary [GU]) toxicity rates after TMT are low and QoL is good [445, 465, 466]. A combined analysis of survivors from four RTOG trials with a median follow-up of 5.4 years showed that combined-modality therapy was associated with low rates of late grade 3 toxicity (5.7% GU and 1.9% GI). No late grade 4 toxicities or treatment-related deaths were recorded [465]. A retrospective study showed QoL to be good after TMT and in most domains better than after cystectomy, although prospective validations are needed [467]. One option to reduce side effects after TMT is the use of IMRT and image-guided radiotherapy (IGRT) [8, 9, 468].

A collaborative review came to the conclusion that data are accumulating, suggesting that bladder preservation with TMT leads to acceptable outcomes and therefore TMT may be considered a reasonable treatment option in well-selected patients as compared to RC [450]. Bladder preservation as an alternative to RC is generally reserved for patients with smaller solitary tumours, negative nodes, no extensive or multifocal CIS, no tumour-related hydrenephrosis, and good pre-treatment bladder function. Trimodality bladder-preserving treatment should also be considered in all patients with a contraindication for surgery, either a relative or absolute contraindication since the factors that determine fitness for surgery and chemoradiotherapy differ. There are no definitive contemporary data supporting the benefit of using neoadjuvant or adjuvant chemotherapy combined with chemoradiation. Patient selection is critical in achieving good outcomes [450]. Whether a node dissection should be performed before TMT as in RC remains unclear [8, 9].

A bladder-preserving trimodality strategy requires very close multidisciplinary cooperation [8, 9]. This was also highlighted by a Canadian group [469]. In Ontario between 1994 and 2008 only 10% (370/3,759) of patients with cystectomy had a pre-operative radiation oncology consultation, with high geographical variations. Independent factors associated with this consultation included advanced age (p < 0.001), greater comorbidity (p < 0.001) and earlier year of diagnosis (p < 0.001). A bladder-preserving trimodality strategy also requires a high level of patient compliance. Even if a patient has shown a clinical response to a trimodality bladder-preserving strategy, the bladder remains a potential source of recurrence, hence long-term life-long bladder monitoring is essential and patients should be counselled that this will be required.

7.5.4.1 Summary of evidence and guidelines for trimodality bladder-preserving treatment

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In a selected patient population, long-term survival rates of trimodality bladder-preserving treatment are comparable to those of early cystectomy.</td>
<td>2b</td>
</tr>
</tbody>
</table>
Recommendations | Strength rating
--- | ---
Offer surgical intervention or trimodality bladder-preserving treatments (TMT) to appropriate candidates as primary curative therapeutic approaches since they are more effective than radiotherapy alone. | Strong
Offer TMT as an alternative to selected, well-informed and compliant patients, especially for whom radical cystectomy is not an option or not acceptable. | Strong

7.5.4.2  **EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [8, 9]**

**Consensus statement**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidates for curative treatment, such as cystectomy or bladder preservation, should be clinically assessed by at least an oncologist, a urologist, a radiation oncologist (in case adjuvant radiotherapy or bladder preservation is considered) and a neutral HCP such as a specialist nurse.</td>
<td></td>
</tr>
<tr>
<td>An important determinant for patient eligibility in case of bladder-preserving treatment is absence of carcinoma in situ.</td>
<td></td>
</tr>
<tr>
<td>An important determinant for patient eligibility in case of bladder-preserving treatment is absence or presence of hydronephrosis.</td>
<td></td>
</tr>
<tr>
<td>When assessing patient eligibility for bladder preservation, the likelihood of successful debulking surgery should be taken into consideration (optimal debulking).</td>
<td></td>
</tr>
<tr>
<td>Bladder urothelial carcinoma with small cell neuroendocrine variant should be treated with neoadjuvant chemotherapy followed by consolidating local therapy.</td>
<td></td>
</tr>
<tr>
<td>In case of bladder preservation with radiotherapy, combination with a radiosensitiser is always recommended to improve clinical outcomes, such as cisplatin, 5FU/TMC, carbogen/nicotinamide or gemcitabine.</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy for bladder preservation should be performed with IMRT and IGRT to reduce side effects.</td>
<td></td>
</tr>
<tr>
<td>Dose escalation above standard radical doses to the primary site in case of bladder preservation, either by IMRT or by brachytherapy, is not recommended.</td>
<td></td>
</tr>
</tbody>
</table>

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).*  
HCP = healthcare professional; IGRT = image-guided radiotherapy; IMRT = intensity-modulated radiotherapy; 5FU = 5-fluorouracil; MMC = mitomycin-C.

7.6  **Adjuvant therapy**

7.6.1   **Role of adjuvant platinum-based chemotherapy**

Adjuvant chemotherapy after RC for patients with pT3/4 and/or LN positive (N+) disease without clinically detectable metastases (M0) is still under debate [457, 470].

The general benefits of adjuvant chemotherapy include:

- chemotherapy is administered after accurate pathological staging, therefore, treatment in patients at low risk for micrometastases is avoided;
- no delay in definitive surgical treatment.

The drawbacks of adjuvant chemotherapy are:

- assessment of in vivo chemosensitivity of the tumour is not possible and overtreatment is an unavoidable problem;
- delay or intolerability of chemotherapy, due to post-operative morbidity [471].

There is limited evidence from adequately conducted and accrued phase III RCTs in favour of the routine use of adjuvant chemotherapy [470, 472-477]. An individual patient data meta-analysis [472] of survival data from six RCTs of adjuvant chemotherapy [454, 478-481] included 491 patients (unpublished data from Otto et al., were included in the analysis). All included trials suffered from significant methodological flaws including small sample size (underpowered), incomplete accrual, use of inadequate statistical methods and design flaws (irrelevant endpoints and failing to address salvage chemotherapy in case of relapse or metastases) [470]. In these trials, three or four cycles of CMV, cisplatin, cyclophosphamide, and adriamycin (CISCA), methotrexate, vinblastine, adriamycin or epirubicin, and cisplatin (MVA(E)C) and cisplatin and methotrexate (CM) were used [482], and one trial used cisplatin monotherapy [480]. The data were not convincing to support an unequivocal recommendation for the use of adjuvant chemotherapy. In 2014, this meta-analysis was updated with an additional three studies [474-476] resulting in the inclusion of 945 patients from nine trials [473]. None of the trials had fully accrued and individual patient data were not used in the analysis [473]. For one trial only an abstract was available at the time of the meta-analysis [475] and none of the included individual trials were significantly positive for OS in favour of adjuvant chemotherapy. In two of the trials more modern chemotherapy
regimens were used (gemcitabine/cisplatin and paclitaxel/gemcitabine/cisplatin) [474, 475]. The HR for OS was 0.77 (95% CI: 0.59–0.99, p = 0.049) and for DFS 0.86 (95% CI: 0.45–0.91, p = 0.014) with a stronger impact on DFS in case of nodal positivity.

A retrospective cohort analysis including 3,974 patients after cystectomy and LND showed an OS benefit in high-risk subgroups (extravesical extension and nodal involvement) (HR: 0.75, CI: 0.62–0.90) [483]. A recent publication of the largest RCT (EORTC 30994), although not fully accrued, showed a significant improvement of PFS for immediate, compared with deferred, cisplatin-based chemotherapy (HR: 0.54, 95% CI: 0.4–0.73, p < 0.0001), but there was no significant OS benefit [484].

Furthermore, a large observational study including 5,653 patients with pathological T3–4 and/or pathological node-positive BC, treated between 2003 and 2006 compared the effectiveness of adjuvant chemotherapy vs. observation. Twenty-three percent of patients received adjuvant chemotherapy with a 5-year OS of 37% for the adjuvant arm vs. 29.1% (HR: 0.70, 95% CI: 0.64–0.76) in the observation group [485].

Another large retrospective analysis based on National Cancer Data Base including 15,397 patients with locally advanced (pT3/4) or LN-positive disease also demonstrated an OS benefit in patients with UC histology [486]. In patients with concomitant variant or pure variant histology, however, no benefit was found.

From the currently available evidence it is still unclear whether immediate adjuvant chemotherapy or chemotherapy at the time of relapse is superior, or if the two approaches are equivalent with respect to the endpoint of OS. The most recent meta-analysis from 2014 showed a therapeutic benefit of adjuvant chemotherapy, but the level of evidence of this review is still very low, with significant heterogeneity and methodological flaws in the only nine included trials [473]. Patients should be informed about potential chemotherapy options before RC, including neoadjuvant and adjuvant chemotherapy, and the limited evidence for adjuvant chemotherapy.

7.6.2 Role of adjuvant immunotherapy
To evaluate the benefit of PD-1/PD-L1 checkpoint inhibitors, a number of randomised phase III trials comparing checkpoint inhibitor monotherapy with atezolizumab, nivolumab or pembrolizumab are under way. Preliminary results of two phase III trials have been presented (atezolizumab at ASCO 2020; nivolumab at ASCO GU 2021): the primary endpoint of improved DFS was not achieved with atezolizumab but was achieved with adjuvant nivolumab. Further results and longer follow-up have to be awaited.

So far, adjuvant immunotherapy is not standard of care and should only be given within a clinical trial [487].

7.6.3 Guidelines for adjuvant therapy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Offer adjuvant cisplatin-based combination chemotherapy to patients with pT3/4 and/or pN+ disease if no neoadjuvant chemotherapy has been given.</td>
<td>Strong</td>
</tr>
<tr>
<td>Only offer immunotherapy with a checkpoint inhibitor in a clinical trial setting.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

7.7 Metastatic disease
7.7.1 Introduction
Approximately 50% of patients with muscle-invasive UC relapse after RC, depending on the pathological stage of the primary tumour and the nodal status. Local recurrence accounts for 30% of relapses, whereas distant metastases are more common. Ten to fifteen percent of patients are already metastatic at diagnosis [488]. Before the development of effective chemotherapy patients with metastatic UC had a median survival rarely exceeding three to six months [489].

7.7.1.1 Prognostic factors and treatment decisions
Prognostic factors are crucial for assessing phase II study results and stratifying phase III trials [490, 491]. In a multivariate analysis, Karnofsky PS of ≤ 80% and presence of visceral metastases were independent prognostic factors of poor survival after treatment with MVAC [491]. These prognostic factors have also been validated for newer combination chemotherapy regimens [492–496]. Two additional prognostic models have been developed in the past years including the variables leukocyte count, number of sites of visceral metastases, site of primary tumour, PS, LN metastasis [496] and visceral metastasis, albumin and haemoglobin [495], respectively.

For patients refractory to, or progressing shortly after, platinum-based combination chemotherapy, four prognostic groups have been established based on three adverse factors that have developed in patients treated with vinflunine and that have been validated in an independent data set; Hb < 10 g/dL presence of liver
metastases and ECOG PS ≥ 1 [497]. It is important to acknowledge that these prognostic models have not been validated in the context of newer agents including immunotherapy.

7.7.1.2 Comorbidity in metastatic disease

Comorbidity is defined as “the presence of one or more disease(s) in addition to an index disease” (see Section 5.3). Comorbidity increases with age. However, chronological age does not necessarily correlate with functional impairment. Different evaluation systems are being used to screen patients as potentially fit or unfit for chemotherapy, but age alone should not be used as the basis for treatment selection [498].

7.7.2 First-line systemic therapy for metastatic disease

In general, patients with untreated metastatic BC can be divided into three broad categories: fit for cisplatin-based chemotherapy, fit for carboplatin-based chemotherapy (but unfit for cisplatin) and unfit for any platinum-based chemotherapy.

7.7.2.1 Definitions: ‘Fit for cisplatin, fit for carboplatin, unfit for any platinum-based chemotherapy’

An international survey among BC experts [499] was the basis for a consensus statement on how to classify patients unfit for cisplatin-based chemotherapy. At least one of the following criteria has to be present: PS > 1; GFR ≤ 60 mL/min; grade ≥ 2 audiometric loss; grade ≥ 2 peripheral neuropathy or New York Heart Association (NYHA) class III heart failure [500]. More than 50% of patients with UC are not eligible for cisplatin-based chemotherapy [501-504]. Renal function assessment in UC is of utmost importance for treatment selection [501, 505]. In case of doubt, measuring GFR with radioisotopes (99mTc DTPA or 51Cr-EDTA) is recommended. Cisplatin has also been administered in patients with a lower GFR (40–60 mL/min) using different split-dose schedules. The respective studies were mostly small phase I and II trials in different settings (neoadjuvant and advanced disease) demonstrating that the use of split-dose cisplatin is feasible and appears to result in encouraging efficacy [506-509]. However, no prospective randomised trial has compared split-dose cisplatin with conventional dosing.

Most patients that are deemed unfit for cisplatin are able to receive carboplatin-based chemotherapy. However, some patients are deemed unfit for any platinum-based chemotherapy (both cisplatin and carboplatin) in case of PS > 2, impaired renal function with a GFR < 30 mL/min or the combination of PS 2 and GFR < 60 mL/min since the outcome in this patient population is poor regardless of platinum-based treatment or not [510]. Patients with multiple comorbidities may also be poor candidates for platinum-based chemotherapy.

7.7.2.2 Chemotherapy in patients fit for cisplatin

Cisplatin-containing combination chemotherapy has been the standard of care since the late 1980s demonstrating an OS of twelve to fourteen months in different series (for a review see [511]). Methotrexate, vinblastine, adriamycin plus cisplatin (MVAC) and GC prolonged survival to up to 14.8 and 13.8 months, respectively, compared to monotherapy and older chemotherapy combinations. Neither of the two combinations is superior to the other but equivalence has not been tested. Response rates were 46% and 49% for MVAC and GC, respectively. The long-term survival results have confirmed the efficacy of the two regimens [512]. The major difference between the above-mentioned combinations is toxicity. The lower toxicity of GC [174] compared to standard MVAC has resulted in it becoming a new standard regimen [513]. Methotrexate, vinblastine, adriamycin plus cisplatin is better tolerated when combined with granulocyte colony-stimulating factor (G-CSF) [513, 514].

High-dose intensity MVAC (HD-MVAC) combined with G-CSF is less toxic and more efficacious than standard MVAC in terms of dose density, complete response (CR), and 2-year survival rate. However, there is no significant difference in median survival between the two regimens [515, 516]. In general, all disease sites have been shown to respond to cisplatin-based combination chemotherapy. A response rate of 66% and 77% with MVAC and HD-MVAC, respectively, has been reported in retroperitoneal LNvs. 29% and 33% at extranodal sites [515]. The disease sites also have an impact on long-term survival. In LN-only disease, 20.9% of patients were alive at five years compared to only 6.8% of patients with visceral metastases [512].

Further intensification of treatment using paclitaxel, cisplatin and gemcitabine (PCG) triple regimen did not result in a significant improvement in OS in the intention-to-treat (ITT) population of a large phase III RCT, comparing PCG triple regimen to GC [517]. However, the overall response rate (ORR) was higher with the triple regimen (56% vs. 44%, p = 0.0031), and the trend for OS improvement in the ITT population (15.8 vs. 12.7 months; HR = 0.85, p = 0.075) became significant in the eligible population.

Carboplatin-containing chemotherapy has not been proven to be equivalent to cisplatin combinations, and should not be considered interchangeable or standard in patients fit for cisplatin. Several phase II RCTs of
carboplatin vs. cisplatin combination chemotherapy have produced lower CR rates and shorter OS for the carboplatin arms [518]. Recently, a retrospective International Study of Advanced/Metastatic Cancer of the Urothelium (RISC) group highlighted the importance of applying the cisplatin-eligibility criteria in order to maintain benefit [519].

7.7.2.3 Chemotherapy in patients fit for carboplatin (but unfit for cisplatin)

Up to 50% of patients are not fit for cisplatin-containing chemotherapy but may be candidates for carboplatin [500]. The first randomised phase II/III trial in this setting was conducted by the EORTC and compared two carboplatin-containing regimens (methotrexate/carboplatin/vinblastine [M-CAVI] and carboplatin/gemcitabine [GemCarbo]) in patients unfit for cisplatin. The EORTC definitions for eligibility were GFR < 60 mL/min and/or PS 2. Both regimens were active. Severe acute toxicity was 13.6% in patients treated with GemCarbo vs. 23% with M-CAVI, while the ORR was 42% for GemCarbo and 30% for M-CAVI. Further analysis showed that in patients with PS 2 and impaired renal function, combination chemotherapy provided very limited benefit [510]. The ORR and severe acute toxicity were both 26% for the former group, and 20% and 24%, respectively, for the latter group [510]. Phase III data have confirmed these results [494]. The combination of carboplatin and gemcitabine can be considered a standard of care in this patient group.

A randomised, international phase II trial (JASINT1; JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin) assessed the efficacy and tolerability profile of two vinflunine-based regimens (vinflunine/gemcitabine vs. vinflunine/carboplatin). Both regimens showed equal ORR and OS with less haematologic toxicity for the combination vinflunine/gemcitabine [520].

7.7.2.4 Integration of immunotherapy in the first-line treatment of patients fit for platinum-based chemotherapy

7.7.2.4.1 Immunotherapy combination approaches

In 2020 the results of three phase III trials have been presented and published investigating the use of immunotherapy in the first-line setting for platinum-eligible patients.

The first trial to report was IMvigor130 investigating the combination of the PD-L1 inhibitor atezolizumab plus platinum-gemcitabine chemotherapy vs. chemotherapy plus placebo vs. atezolizumab alone [521]. The primary endpoint of PFS benefit for the combination vs. chemotherapy alone in the ITT group was reached (8.2 months vs. 6.3 months [HR: 0.82, 95% CI: 0.70–0.96; one-sided, p = 0.007]) while OS was not significant at the interim analysis after a median follow-up of 11.8 months. The small PFS benefit in the absence of an OS benefit has raised questions of its clinical significance. Due to the sequential testing design, the comparison of chemotherapy vs. atezolizumab alone has not yet been formally performed.

The KEYNOTE 361 study had a very similar design using the PD-1 inhibitor pembrolizumab plus platinum-gemcitabine vs. chemotherapy alone vs. pembrolizumab alone. The results of the primary endpoints of PFS and OS for the comparison of pembrolizumab plus chemotherapy vs. chemotherapy in the ITT population have been presented but are not yet fully published and show no benefit for the combination [522].

DANUBE compared the immunotherapy combination (IO-IO) of CTLA-4 inhibitor tremelimumab and PD-L1 inhibitor durvalumab with chemotherapy alone or durvalumab alone [523]. The co-primary endpoint of improved OS for the IO-IO combination vs. chemotherapy was not reached in the ITT group nor was the OS improved for durvalumab monotherapy vs. chemotherapy in the PD-L1-positive population.

In conclusion; at this time these three trials do not support the use of combination of PD-1/L1 checkpoint inhibitors plus chemotherapy or the IO-IO combination.

7.7.2.4.2 Use of single-agent immunotherapy

Based on the results of two single-arm phase II trials [524, 525] the checkpoint inhibitors pembrolizumab and atezolizumab have been approved by the FDA and the EMA for first-line treatment in cisplatin-unfit patients in case of positive PD-L1 status. Programmed death-ligand-1 positivity for use of pembrolizumab is defined by immunohistochemistry as a combined positive score (CPS) of ≥ 10 using the Dako 22C33 platform and for atezolizumab as positivity of ≥ 5% tumour-infiltrating immune cells using Ventana SP142.

The PD-1 inhibitor pembrolizumab was tested in 370 patients with advanced or metastatic UC ineligible for cisplatin, showing an ORR of 29% and complete remission in 7% of patients [524]. The PD-L1 inhibitor atezolizumab was also evaluated in the same patient population in a phase II trial (n = 119) showing an ORR of 23% with 9% of patients achieving a complete remission; median OS was 15.9 months [525]. The results are difficult to interpret due to the missing control arm and the heterogeneity of the study population with regards to PD-L1 status.

The trials IMvigor 130, Keynote 361 and DANUBE all included an experimental arm with immunotherapy alone using atezolizumab, pembrolizumab and durvalumab, respectively [521-523].
results presented so far have not demonstrated a benefit in terms of PFS or OS compared to platinum-based chemotherapy but no subgroup comparisons for cisplatin-unfit patients were analysed.

7.7.2.4.3 Switch maintenance with immunotherapy
The JAVELIN Bladder 100 study investigated the impact of switch maintenance with the PD-L1 inhibitor avelumab after initial treatment with platinum-gemcitabine combination [526]. Patients achieving at least stable disease, or better, after 4–6 cycles of platinum-gemcitabine were randomised to avelumab or best supportive care (BSC). Overall survival was the primary endpoint which improved to 21.4 months with avelumab compared to 14.3 months with BSC (HR: 0.69, 95% CI: 0.56–0.86; p < 0.001). Of patients who discontinued BSC and received subsequent treatment 53% received immunotherapy. Grade 3 or higher side effects occurred in 47% of avelumab patients compared to 25% of BSC patients. Immune-related adverse events occurred in 29% of all patients and 7% experienced grade 3 complications which included colitis, pneumonitis, rash, increased liver enzymes, hyperglycaemia, myositis and hypothyroidism.

A randomised phase II trial evaluated switch maintenance treatment with pembrolizumab in patients achieving at least stable disease on platinum-based first-line chemotherapy [527]. One hundred and eight patients were randomised to pembrolizumab or placebo. At a median follow-up of 12.9 months (range 0.9–34.5 months), the primary endpoint of PFS was met (5.4 months vs. 3.0 months, HR: 0.65, p = 0.04) but not the secondary endpoint of OS (22 months vs. 18.7 months, HR: 0.91, 95% CI: 0.52–1.59).

7.7.2.5 Treatment of patients unfit for any platinum-based chemotherapy
Limited data exists regarding the optimal treatment for this patient population which is characterised by impaired PS (PS > 2) and/or impaired renal function (GFR < 30 mL/min). Historically, the outcome in this patient group has been poor. Often BSC has been chosen instead of systemic therapy. Most trials evaluating alternative treatment options to cisplatinum-based chemotherapy did not focus specifically on this patient population thereby making interpretation of data difficult. The FDA (but not EMA) has approved pembrolizumab and atezolizumab as first-line treatment for patients not fit to receive any platinum-based chemotherapy regardless of PD-L1 status based on the results of two single-arm phase II trials [524, 525]. It has not been reported how many patients in these two studies were unfit for any platinum-based chemotherapy.

7.7.2.6 Non-platinum combination chemotherapy
The use of single-agent chemotherapy has been associated with varying response rates. Responses with single agents are usually short-lived, complete responses are rare, and no long-term DFS/OS has been reported.

Different combinations of gemcitabine and paclitaxel have been studied as first- and second-line treatments. Apart from severe pulmonary toxicity with a weekly schedule of both drugs, this combination is well tolerated and produces response rates between 38% and 60% in both lines. Non-platinum combination chemotherapy has not been compared to standard platinum-based chemotherapy in RCTs; therefore, it is not recommended for first-line use in platinum-eligible patients [528-535].

7.7.3 Second-line systemic therapy for metastatic disease
7.7.3.1 Second-line chemotherapy
Second-line chemotherapy data are highly variable and mainly derive from small single-arm phase II trials apart from a single randomised phase III study [497]. A reasonable strategy has been to re-challenge former cisplatin-sensitive patients if progression occurred at least six to twelve months after first-line cisplatin-based combination chemotherapy. Second-line response rates of single-agent treatment with paclitaxel (weekly), docetaxel, nab-paclitaxel (nanoparticle albumin-bound) [536] oxaliplatin, ifosfamide, topotecan, pemetrexed, lapatinib, gefitinib and bortezomib have ranged between 0% and 28% in small phase II trials [537-539]. Gemcitabine has also shown response in second-line use but most patients receive this drug as part of their first-line treatment [535].

The paclitaxel/gemcitabine combination has shown response rates of 38–60% in small single-arm studies. No phase III RCT with an adequate comparator arm has been conducted to assess the true value and OS benefit of this second-line combination [489, 533, 540].

Vinflunine, a third-generation vinca alkaloid, was tested in a phase III RCT and compared against BSC in patients progressing after first-line treatment with platinum-containing combination chemotherapy for metastatic disease [541]. The results showed a modest ORR (8.6%), a clinical benefit with a favourable safety profile and a survival benefit in favour of vinflunine, which was, however, only statistically significant in the eligible patient population (not in the ITT population).

Vinflunine was approved as second-line treatment in Europe (not in the U.S.). More recently, second-line therapy with PD-1/PD-L1 checkpoint inhibitors has been established as standard second-line
therapy and vinflunine is reserved for patients with contraindications to immunotherapy and may be considered as third- or later-line treatment option although no randomised data for these indications exist.

A randomised phase III trial evaluated the addition of the angiogenesis inhibitor ramucirumab to docetaxel chemotherapy vs. docetaxel alone, which resulted in improved PFS (4.07 vs. 2.76 months) and higher response rates (24.5% vs. 14%), respectively [542]. While the primary endpoint of PFS prolongation was reached, the clinical benefit appears small and no OS benefit has been shown [543].

7.7.3.2 Second-line immunotherapy for platinum-pre-treated patients
The immune checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab have demonstrated similar efficacy and safety in patients progressing during, or after, standard platinum-based chemotherapy in phase I, II and III trials.

Pembrolizumab, a PD-1 inhibitor, has been tested in patients progressing during or after platinum-based first-line chemotherapy in a phase III RCT and demonstrated a significant OS benefit leading to approval. In the trial, patients (n = 542) were randomised to receive either pembrolizumab monotherapy or chemotherapy (paclitaxel, docetaxel or vinflunine). The median OS in the pembrolizumab arm was 10.3 months (95% CI: 8.0–11.8) vs. 7.4 months (95% CI: 6.1–8.3) for the chemotherapy arm (HR for death, 0.73, 95% CI: 0.59–0.91, p = 0.002) independent of PD-L1 expression levels [544]. This trial was recently updated with a longer follow-up of 27.7 months showing consistent improvement of OS [545]. In addition, HRQoL analysis showed that patients on pembrolizumab experience stable, or improved, HRQoL, whereas it deteriorated on chemotherapy [546].

Atezolizumab, a PD-L1 inhibitor, tested in patients progressing during, or after, previous platinum-based chemotherapy in phase I, phase II and phase III trials, was the first checkpoint inhibitor approved for BC [204, 547, 548]. The phase III RCT (IMvigor211) included 931 patients comparing atezolizumab with second-line chemotherapy (either paclitaxel, docetaxel or vinflunine) did not meet its primary endpoint of improved OS for patients with high PD-L1 expression (immune cells [IC] score 2/3) with 11.1 months (atezolizumab) vs. 10.6 (chemotherapy) months (stratified HR: 0.87, 95% CI: 0.63–1.21, p = 0.41) but OS was numerically improved in the ITT population in an exploratory analysis (8.6 months vs. 8.0 months, HR: 0.85, 95% CI: 0.73–0.99). A phase IV single-arm safety study was conducted with atezolizumab including 1,004 patients confirming the efficacy and tolerability profile [549].

The PD-1 inhibitor nivolumab was approved based on the results of a single-arm phase II trial (CheckMate 275), enrolling 270 platinum pre-treated patients. The first endpoint was ORR. Objective response rate was 19.6%, and OS was 8.74 months for the entire group [550]. Based on results of phase I/II and phase IB trials, two additional PD-L1 inhibitors, durvalumab and avelumab, are currently only approved for this indication in the U.S. [551-553].

7.7.3.2.1 Side-effect profile of immunotherapy
Checkpoint inhibitors including PD-1 or PD-L1 antibodies and CTLA-4 antibodies have a distinct side effect profile associated with their mechanism of action leading to enhanced immune system activity. These adverse events can affect any organ in the body leading to mild, moderate or severe side effects. The most common organs affected are the skin, gastrointestinal tract, liver, lung, thyroid, adrenal and pituitary gland. Other systems that may be affected include musculoskeletal, renal, nervous, haematologic, ocular and cardiovascular system. Any change during immunotherapy treatment should raise suspicion about a possible relation to the treatment. The nature of immune-related adverse events has been very well characterised and published [554].

The timely and appropriate treatment of immune-related side effects is crucial to achieve optimal benefit from the treatment while maintaining safety. Clear guidelines for side effect management have been published [555]. Immunotherapy treatment should be applied and supervised by trained clinicians only to ensure early side effect recognition and treatment.

In case of interruption of immunotherapy, re-challenge will require close monitoring for adverse events [556].

7.7.4 Novel agents for second- or later-line therapy
Genomic profiling of urothelial carcinoma has revealed common potentially actionable genomic alterations including alterations in FGFR [557]. Erdafitinib is a pan-FGFR tyrosine kinase inhibitor and the first FDA-approved targeted therapy for metastatic urothelial carcinoma with susceptible FGFR2/3 alterations following platinum-containing chemotherapy. The phase II trial of erdafitinib included 99 patients whose tumour harboured an FGFR3 mutation or FGFR2/3 fusion and who had disease progression following chemotherapy [202]. The confirmed ORR was 40% and an additional 39% of patients had stable disease. A total of 22 patients had previously received immunotherapy with only one patient achieving a response, yet the response
rate for erdafitinib for this subgroup was 59%. At a median follow-up of 24 months, the median PFS was 5.5 months (95% CI: 4.0–6.0) and the median OS was 11.3 months (95% CI: 9.7–15.2) [202]. Treatment-related adverse events of ≥ grade 3 occurred in 46% of patients. Common adverse events of ≥ grade 3 were hyponatraemia (11%), stomatitis (10%), and asthenia (7%) and 13 patients discontinued erdafitinib due to adverse events, including retinal pigment epithelial detachment, hand-foot syndrome, dry mouth, and skin/nail events. In addition to erdafitinib, several other FGFR inhibitors are being evaluated including infigratinib which has demonstrated promising activity [203]. The increased identification of FGFR3 mutations/fusion in UTUCs and in NMIBC has led to several ongoing trials.

Another promising drug is enfortumab vedotin, an antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule which is highly expressed in UC conjugated to monomethyl auristatin E (MMAE). A published phase-II single-arm study (n = 125) in patients previously treated with platinum chemotherapy and checkpoint inhibition showed a confirmed objective response rate of 44%, including 12% complete responses [558]. Responses were seen across patient subgroups including 41% in checkpoint inhibitor non-responders and 38% in patients with liver metastases. The most common treatment-related AEs included fatigue (50%), alopecia (48%), and decreased appetite (41%). Treatment-related AEs of interest included any rash (48% all grade, 11% ≥ G3) and any peripheral neuropathy (50% all grade, 3% ≥ G3). This data led to the accelerated FDA approval for enfortumab vedotin in locally advanced or metastatic UC patients who have previously received a PD-1 or PD-L1 inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting [559]. A phase III RCT comparing enfortumab vedotin with single-agent chemotherapy has reported preliminary results (ASCO GU 2021), reporting a significant survival benefit [558]. Another ongoing trial has reported promising activity for the combination of enfortumab vedotin in combination with pembrolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced/metastatic UC (ORR: 73.3% with 15.6% complete responses) [560]. Another promising ADC is sacituzumab govitecan, targeting trophoblast cell surface antigen 2 (Trop-2) conjugated to SN-38, the active metabolite of irinotecan [561].

7.7.5 Post-chemotherapy surgery and oligometastatic disease

With cisplatin-containing combination chemotherapy, excellent response rates may be obtained in patients with LN metastases only, good PS and adequate renal function, including a high number of complete responses with up to 20% of patients achieving long-term DFS [512, 516, 562, 563]. The role of surgery of residual LNs after chemotherapy is still unclear. Although some studies suggest a survival benefit and QoL improvement, the level of evidence supporting this practice is mainly anecdotal [564-578]. Retrospective studies of post-chemotherapy surgery after partial or complete remission have indicated that surgery may contribute to long-term DFS in selected patients [579-582]. These findings have been confirmed in a recent systematic review including 28 studies [582].

In the absence of data from RCTs, patients should be evaluated on an individual basis and discussed by an interdisciplinary tumour board [582].

7.7.6 Treatment of patients with bone metastases

The prevalence of metastatic bone disease (MBD) in patients with advanced/metastatic UC is 30–40% [583]. Skeletal complications due to MBD have a detrimental effect on pain and QoL and are also associated with increased mortality [584]. Bisphosphonates such as zoledronic acid reduce and delay skeletal-related events (SREs) due to bone metastases by inhibiting bone resorption, as shown in a small pilot study [585]. Denosumab, a fully human monoclonal antibody that binds to and neutralises RANKL (receptor activator of nuclear factor B ligand), was shown to be non-inferior to zoledronic acid in preventing or delaying SREs in patients with solid tumours and advanced MBD, including patients with UC [586]. Patients with MBD, irrespective of the cancer type, should be considered for bone-targeted treatment [584].

Patients treated with zoledronic acid or denosumab should be informed about possible side effects including osteonecrosis of the jaw and hypocalcaemia. Supplementation with calcium and vitamin D is mandatory. Dosing regimens of zoledronic acid should follow regulatory recommendations and have to be adjusted according to pre-existing medical conditions, especially renal function [587]. For denosumab, no dose adjustments are required for variations in renal function.
### Summary of evidence and guidelines for metastatic disease

#### Summary of evidence

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In a first-line setting, performance status (PS) and the presence or absence of visceral metastases are independent prognostic factors for survival.</td>
<td>1b</td>
</tr>
<tr>
<td>In a second-line setting, negative prognostic factors are: liver metastasis, PS ≥ 1 and low haemoglobin (&lt; 10 g/dL). Cisplatin-containing combination chemotherapy can achieve median survival of up to 14 months, with long-term disease-free survival (DFS) reported in ~15% of patients with nodal disease and good PS.</td>
<td>1b</td>
</tr>
<tr>
<td>Single-agent chemotherapy provides low response rates of usually short duration.</td>
<td>2a</td>
</tr>
<tr>
<td>Carboplatin combination chemotherapy is less effective than cisplatin-based chemotherapy in terms of complete response and survival.</td>
<td>2a</td>
</tr>
<tr>
<td>Non-platinum combination chemotherapy has not been tested against standard chemotherapy in patients who are fit or unfit for cisplatin-combination chemotherapy.</td>
<td>4</td>
</tr>
<tr>
<td>There is no defined standard therapy for platinum chemotherapy-unfit patients with advanced or metastatic urothelial cancer (UC).</td>
<td>2b</td>
</tr>
<tr>
<td>Post-chemotherapy surgery after partial or complete response may contribute to long-term DFS in selected patients.</td>
<td>3</td>
</tr>
<tr>
<td>Zoledronic acid and denosumab have been approved for supportive treatment in case of bone metastases of all cancer types including UC, as they reduce and delay skeletal related events.</td>
<td>1b</td>
</tr>
<tr>
<td>PD-1 inhibitor pembrolizumab has been approved for patients that have progressed during or after previous platinum-based chemotherapy based on the results of a phase III trial.</td>
<td>1b</td>
</tr>
<tr>
<td>PD-L1 inhibitors atezolizumab, nivolumab, durvalumab and avelumab have been FDA approved for patients that have progressed during or after previous platinum-based chemotherapy based on the results of a phase II trial.</td>
<td>2a</td>
</tr>
<tr>
<td>PD-1 inhibitor pembrolizumab and PD-L1 inhibitor atezolizumab have been approved for patients with advanced or metastatic UC unfit for cisplatinum-based first-line chemotherapy and with overexpression of PD-L1 based on the results of single-arm phase II trials.</td>
<td>2a</td>
</tr>
<tr>
<td>The combination of chemotherapy plus pembrolizumab or atezolizumab and the combination of durvalumab and tremelimumab have not demonstrated OS survival benefit compared to platinum-based chemotherapy alone.</td>
<td>1b</td>
</tr>
<tr>
<td>Switch maintenance with the PD-L1 inhibitor avelumab has demonstrated significant OS benefit in patients achieving at least stable disease on first-line platinum-based chemotherapy.</td>
<td>1b</td>
</tr>
</tbody>
</table>

#### Recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line treatment for platinum-fit patients</strong></td>
<td></td>
</tr>
<tr>
<td>Use cisplatin-containing combination chemotherapy with GC or HD-MVAC.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients unfit for cisplatin but fit for carboplatin use the combination of carboplatin and gemcitabine.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients achieving stable disease, or better, after first-line platinum-based chemotherapy use maintenance treatment with PD-L1 inhibitor avelumab.</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>First-line treatment in patients unfit for platinum-based chemotherapy</strong></td>
<td></td>
</tr>
<tr>
<td>Consider checkpoint inhibitors pembrolizumab or atezolizumab.</td>
<td>Weak</td>
</tr>
<tr>
<td><strong>Second-line treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Offer checkpoint inhibitor pembrolizumab to patients progressing during, or after, platinum-based combination chemotherapy for metastatic disease. If this is not possible, offer atezolizumab, nivolumab (EMA, FDA approved); avelumab or durvalumab (FDA approved).</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>Further treatment after platinum- and immunotherapy</strong></td>
<td></td>
</tr>
<tr>
<td>Offer treatment in clinical trials testing novel antibody drug conjugates (enfortumab vedotin, sacituzumab govitecan); or in cases of patients with FGFR3 alterations, FGFR tyrosine kinase inhibitors.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

**GC** = gemcitabine plus cisplatin; **FGFR** = fibroblast growth factor receptor; **HD-MVAC** = high-dose intensity methotrexate, vinblastine, adriamycin plus cisplatin.
Figure 7.2: Flow chart for the management of metastatic urothelial cancer*

*Treatment within clinical trials is highly encouraged.

BSC = best supportive care; CR = complete response; DD-MVAC = dose dense methotrexate vinblastine doxorubicin cisplatin; EV = enfortumab vedotin; FDA = US Food and Drug Administration; FGFR = pan-fibroblast growth factor receptor tyrosine kinase inhibitor; GFR = glomerular filtration rate; IO = immunotherapy; PR = partial response; PS = performance status; SD = stable disease.

7.8 Quality of life

7.8.1 Introduction
The evaluation of HRQoL considers physical, psychological, emotional and social functioning. In patients with MIBC, HRQoL declines in particular in the physical and social functioning domains [588]. Several questionnaires have been validated for assessing HRQoL in patients with BC, including FACT (Functional Assessment of Cancer Therapy)-G [589], EORTC QLQ-C30 [590], EORTC QLQ-BLM (MIBC module) [591], and SF (Short Form)-36 [592, 593] and recently the BCI questionnaire specifically designed and validated for BC patients [594].

7.8.2 Neoadjuvant chemotherapy
The impact of NAC on patient-reported outcomes (using EORTC QLQ questionnaires) was investigated by Feuerstein et al. [595]. A propensity-matched analysis of 101 patients who completed NAC and 54 patients who did not undergo NAC, showed no negative effect of NAC on patient-reported outcomes. Similar results were reported by Huddart et al., based on data from the BC2001 trial [466].
7.8.3 Radical cystectomy and urinary diversion

Two systematic reviews and meta-analyses focused on HRQoL after RC and urinary diversion [351, 596].

Yang et al. compared HRQoL of incontinent and continent urinary diversions (all types) including 29 studies (n = 3,754) of which 9 had a prospective design (one of which was randomised) [351]. Only three studies reported HRQoL data both pre- and post-operatively. In these three studies, an initial deterioration in overall HRQoL was reported but general health, functional and emotional domains at 12 months post-surgery were equal or better than baseline. After 12 months, the HRQoL benefits diminished in all domains. Overall, no difference in HRQoL between continent and incontinent urinary diversion was reported although an ileal conduit may confer a small physical health benefit [596].

Cerruto et al. reported HRQoL comparing ileal conduit with orthotopic neobladder reconstruction [596]. A pooled analysis was performed including 18 studies (n = 1,553) of which the vast majority were retrospective studies. The analysis showed no statistical significant difference in overall HRQoL, but methodological limitations need to be considered.

Clifford et al. prospectively evaluated continence outcomes in male patients undergoing orthotopic neobladder diversion [597]. Day-time continence increased from 59% at less than three months post-operatively to 92% after 12 to 18 months. Night-time continence increased from 28% at less than three months post-operatively to 51% after 18 to 36 months. Also of interest is the urinary bother in females with an orthotopic neobladder. Bartsch and co-workers reported day-time and night-time continence rates of 70.4% and 64.8%, respectively, in 56 female neobladder patients. Thirty-five patients (82.5%) performed clean intermittent catheterisation, which is much worse when compared to male neobladder patients. Moreover, patients with non-organ-confined disease (p = 0.04) and patients with a college degree (p = 0.001) showed worse outcomes on HRQoL scores [598].

Altogether, there is no superior type of urinary diversion in terms of overall HRQoL in unselected patients. Health-related QoL outcomes are most likely a result of good patient selection. An older, more isolated, patient is probably better served with an ileal conduit, whereas a younger patient with a likely higher level of interest in body image and sexuality is better off with an orthotopic diversion. The patient’s choice is the key to the selection of reconstruction method [351].

7.8.4 Bladder sparing trimodality therapy

The only HRQoL data in bladder sparing treatment collected in an RCT setting was published by Huddart et al. [466]. The primary endpoint was the change in the Bladder Cancer Subscale (BLCS), as part of the FACT-BL questionnaire, at one year post-treatment. Questionnaire return rate at one and five years was 70% and 60%, respectively. The remaining patients did mostly not respond as a result of recurrence or RC. The data show a reduction in HRQoL in the majority of the domains immediately following radiotherapy but in most patients the HRQoL scores returned to baseline 6 months after RT and maintained at this level for five years. Approximately 33% of patients reported persistent lower Bladder Cancer Subscale scores after five years. Addition of chemotherapy did not affect the HRQoL outcomes.

7.8.5 Non-curable or metastatic bladder cancer

In non-curable or metastatic BC, HRQoL is reduced because of associated micturition problems, bleeding, pain and therefore disturbance of social and sexual life [599]. There is limited literature describing HRQoL in BC patients receiving palliative care [600] but there are reports of bladder-related symptoms relieved by palliative surgery [423], RT [601], and/or chemotherapy [602].

A HRQoL analysis was performed in platinum-refractory patients who were randomised to pembrolizumab vs. another line of chemotherapy (KEYNOTE-45 trial) [546]. It was reported that patients treated with pembrolizumab had stable or improved global health status/QoL, whereas those treated with investigators’ choice of chemotherapy experienced declines in global health [546].

7.8.6 Summary of evidence and recommendations for health-related quality of life

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compared to non-cancer controls, the diagnosis and treatment of bladder cancer has a negative impact on HRQoL.</td>
<td>2a</td>
</tr>
<tr>
<td>There is no significant difference in overall QoL between patients with continent or incontinent diversion.</td>
<td>2a</td>
</tr>
<tr>
<td>In patients with MIBC treated with RC, overall HRQoL declines immediately after treatment and recovers to baseline at 12 months post-operatively.</td>
<td>1a</td>
</tr>
</tbody>
</table>
In patients with MIBC treated with radiotherapy, overall HRQoL declines immediately after treatment. In most patients, overall HRQoL then recovers to baseline at 6 months and maintains at this level to 5 years.

In patients with MIBC treated with radiotherapy, concomitant chemotherapy or neo-adjuvant chemotherapy has no significant impact on HRQoL.

In patients with platinum-refractory advanced urothelial carcinoma, pembrolizumab may be superior in terms of HRQoL compared to another line of chemotherapy.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use validated questionnaires to assess health-related quality of life in patients with muscle-invasive bladder cancer.</td>
<td>Strong</td>
</tr>
<tr>
<td>Discuss the type of urinary diversion taking into account a patient preference, existing comorbidities, tumour variables and coping abilities.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

### 8. FOLLOW-UP

#### 8.1 Follow-up in muscle invasive bladder cancer

An appropriate schedule for disease monitoring should be based on natural timing of recurrence; probability and site of recurrence; functional monitoring after urinary diversion and the potential available management options [603].

Nomograms on CSS following RC have been developed and externally validated, but their wider use cannot be recommended until further data become available [604, 605].

Current surveillance protocols are based on patterns of recurrence drawn from retrospective series only. Combining this data is not possible since most retrospective studies use different follow-up regimens and imaging techniques. Additionally, reports of asymptomatic recurrences diagnosed during routine oncological follow-up and results from retrospective studies are contradictory [606-608]. From the Volkmer B, et al. series of 1,270 RC patients, no differences in OS were observed between asymptomatic and symptomatic recurrences [607]. Conversely, in the Giannarini, et al. series of 479 patients; those with recurrences detected during routine follow-up (especially in the lungs) and with secondary urothelial tumours as the site of recurrence, had a slightly higher survival [606]. Boorjian, et al. included 1,599 RC patients in their series, with 77% symptomatic recurrences. On multivariate analysis, patients who were symptomatic at recurrence had a 60% increased risk of death as compared to asymptomatic patients [608].

However, at this time, no data from prospective trials demonstrating the potential benefit of early detection of recurrent disease and its impact on OS are available [609]. For details see Section 7.5.4.

#### 8.2 Site of recurrence

##### 8.2.1 Local recurrence

Local recurrence takes place in the soft tissues of the original surgical site or in LNs. Contemporary cystectomy has a 5–15% probability of pelvic recurrence which usually occurs during the first 24 months, most often within 6 to 18 months after surgery. However, late recurrences can occur up to five years after RC. Risk factors described are pathological stage, LNs, positive margins, extent of LND and peri-operative chemotherapy [610].

Patients generally have a poor prognosis after pelvic recurrence. Even with treatment, median survival ranges from four to eight months following diagnosis. Definitive therapy can prolong survival, but mostly provides significant palliation of symptoms. Trimodality management generally involves a combination of chemotherapy, radiation and surgery [609].

##### 8.2.2 Distant recurrence

Distant recurrence is seen in up to 50% of patients treated with RC for MIBC. As with local recurrence, pathological stage and nodal involvement are risk factors [611]. Systemic recurrence is more common in locally advanced disease (pT3/4), ranging from 32 to 62%, and in patients with LN involvement (range 52–70%) [612].

The most likely sites for distant recurrence are LNs, lungs, liver and bone. Nearly 90% of distant recurrences appear within the first three years after RC, mainly in the first two years, although late recurrence has been described after more than 10 years. Median survival of patients with progressive disease treated with platinum-based chemotherapy is 9–26 months [613-615]. However, longer survival (28–33% at 5 years) has been reported in patients with minimal metastatic disease undergoing trimodality management, including metastasectomy [565, 573].
8.2.3 Urothelial recurrences

After RC, the incidence of new urethral tumours was 4.4% (1.3–13.7%). Risk factors for secondary urethral tumours are urethral malignancy in the prostatic urethra/prostate (in men) and bladder neck (in women). Orthotopic neobladder was associated with a significant lower risk of urethral tumours after RC (OR: 0.44) [616].

There is limited data, and agreement, about urethral follow-up, with some authors recommending routine surveillance with urethral wash and urine cytology and others doubting the need for routine urethral surveillance. However, there is a significant survival advantage in men with urethral recurrence diagnosed asymptptomatically vs. symptomatically, so follow-up of the male urethra is indicated in patients at risk of urethral recurrence [609]. Treatment is influenced by local stage and grade of urethral occurrence. In urethral CIS, BCG instillations have success rates of 83% [617]. In invasive disease, urethrectomy should be performed if the urethra is the only site of disease; in case of distant disease, systemic chemotherapy is indicated [3].

Upper urinary tract UCs occur in 4–10% of cases and represent the most common sites of late recurrence (3-year DFS following RC) [618]. Median OS is 10–55 months, and 60–67% of patients die of metastatic disease [609]. A meta-analysis found that 38% of UTUC recurrence was diagnosed by follow-up investigations, whereas in the remaining 62%, diagnosis was based on symptoms. When urine cytology was used during surveillance, the rate of primary detection was 7% vs. 29.6% with UUT imaging. The meta-analysis concluded that patients with non-invasive cancer are twice as likely to have UTUC as patients with invasive disease [619]. Multifocality increases the risk of recurrence by three-fold, while positive ureteral or urethral margins increase the risk by seven-fold. Radical nephroureterectomy can prolong survival [620].

8.3 Time schedule for surveillance

Although, based on low level evidence only, some follow-up schedules have been suggested, guided by the principle that recurrences tend to occur within the first years following initial treatment. A schedule suggested by the EAU Guidelines Panel includes a CT scan (every 6 months) until the third year, followed by annual imaging thereafter. Patients with multifocal disease, NMIBC with CIS or positive ureteral margins are at higher risk of developing UTUC, which can develop late (> 3 years). In those cases, monitoring of the UUT is mandatory during follow-up. Computed tomography is to be used for imaging of the UUT [619].

The exact time to stop follow-up is not well known and recently a risk-adapted schedule has been proposed, based on the interaction between recurrence risk and competing health factors that could lead to individualised recommendations and may increase recurrence detection. Elderly and very low-risk patients (those with NMIBC or pT0 disease at final cystectomy report) showed a higher competing risk of non-BC mortality when compared with their level of BC recurrence risk. On the other hand, patients with locally advanced disease or LN involvement are at a higher risk of recurrence for more than 20 years [621]. However, this model has not been validated and does not incorporate several risk factors related to non-BC mortality. Furthermore, the prognostic implications of the different sites of recurrence should be considered. Local and systemic recurrences have a poor prognosis and early detection of the disease will not influence survival [622]. Despite this, the rationale for a risk-adapted schedule for BC surveillance appears to be promising and deserves further investigation.

Since data for follow-up strategies are sparse, a number of key questions were included in a recently held consensus project [8, 9]. Outcomes for all statements for which consensus was achieved are listed in Section 8.6.

8.4 Follow-up of functional outcomes and complications

Apart from oncological surveillance, patients with a urinary diversion need functional follow-up. Complications related to urinary diversion are detected in 45% of patients during the first five years of follow-up. This rate increases over time, and exceeds 54% after 15 years of follow-up. In a single-centre series of 259 male patients, long-term follow-up after orthotopic bladder substitution (median 121 months [range 60–267]), showed that excellent long-term functional outcomes can be achieved in high-volume centres with dedicated teams [623]. A smaller multi-centre series including women only (n = 102) showed complication rates between 5–12% after orthotopic neobladder (median follow up of 24 months [range 1.5–100 months]). Both early (5%) and late (12%) complications related to the urinary diversion [624].

The functional complications are diverse and include: vitamin B12 deficiency, metabolic acidosis, worsening of renal function, urinary infections, urolithiasis, stenosis of uretero-intestinal anastomosis, stoma complications in patients with ileal conduit, neobladder continence problems, and emptying dysfunction [609]. Functional complications are especially common in women: approximately two-thirds need to catheterise their neobladder, while almost 45% do not void spontaneously at all [598]. There seems to be a correlation between
voiding patterns and nerve preservation; in 66 women bilateral preservation of autonomic nerves decreased the need for catheterisation to between 3.4–18.7% (CI: 95%) [624].

Recently a 21% increased risk of fractures was also described as compared to no RC due to chronic metabolic acidosis and subsequent long-term bone loss [622]. Since low vitamin B12 levels have been reported in 17% of patients with bowel diversion, in case of cystectomy and bowel diversion, vitamin B12 levels should be measured annually [8, 9, 378].

8.5 Summary of evidence and recommendations for specific recurrence sites

<table>
<thead>
<tr>
<th>Site of recurrence</th>
<th>Summary of evidence</th>
<th>Recommendation</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local recurrence</td>
<td>Poor prognosis.</td>
<td>Offer radiotherapy, chemotherapy and possibly surgery as options for treatment, either alone or in combination.</td>
<td>Strong</td>
</tr>
<tr>
<td>Distant recurrence</td>
<td>Poor prognosis.</td>
<td>Offer chemotherapy as the first option, and consider metastasectomy or radiotherapy in case of unique metastasis site.</td>
<td>Strong</td>
</tr>
<tr>
<td>Upper urinary tract recurrence</td>
<td>Risk factors are multifocal disease (NMIBC/CIS or positive ureteral margins).</td>
<td>See EAU Guidelines on Upper Urinary Tract Urothelial Carcinomas.</td>
<td>Strong</td>
</tr>
<tr>
<td>Secondary urethral tumour</td>
<td>Staging and treatment should be done as for primary urethral tumour.</td>
<td>See EAU Guidelines on Primary Urethral Carcinoma.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

8.6 EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [8, 9]*

**Consensus statement**

After radical cystectomy with curative intent, regular follow-up is needed.

After radical cystectomy with curative intent, follow-up for the detection of second cancers in the urothelium is recommended.

After radical cystectomy with curative intent, follow-up of the urethra with cytology and/or cystoscopy is recommended in selected patients (e.g., multifocality, carcinoma in situ and tumour in the prostatic urethra).

After trimodality treatment with curative intent, follow-up for the detection of relapse is recommended every 3–4 mos initially; then after 3 yrs, every 6 mos in the majority of patients.

After trimodality treatment with curative intent, regular follow-up for the detection of relapse is needed in the majority of patients.

In patients with a partial or complete response after chemotherapy for metastatic urothelial cancer, regular follow-up is needed. Imaging studies may be done according to signs/symptoms.

To detect relapse (outside the bladder) after trimodality treatment with curative intent, CT of the thorax and abdomen is recommended as the imaging method for follow-up in the majority of patients.

To detect relapse (outside the bladder) after trimodality treatment with curative intent, routine imaging with CT of the thorax and abdomen should be stopped after 5 yrs in the majority of patients.

In patients treated with radical cystectomy with curative intent and who have a neobladder, management of acid bases household includes regular measurements of pH and sodium bicarbonate substitution according to the measured value.

To detect relapse after radical cystectomy with curative intent, routine imaging with CT of the thorax and abdomen should be stopped after 5 yrs in the majority of patients.
To detect relapse after radical cystectomy with curative intent, a CT of the thorax and abdomen is recommended as the imaging method for follow-up in the majority of patients.

Levels of LDH and CEA are not essential in the follow-up of patients with urothelial cancer to detect recurrence.

Vitamin B12 levels have to be measured annually in the follow-up of patients treated with radical cystectomy and bowel diversion with curative intent.

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

CEA = carcinoembryonic antigen; CT = computed tomography; LDH = lactate dehydrogenase; mos = months; yrs = years.

9. REFERENCES


10. IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021 [access date March 2021]. https://gco.iarc.fr/today/online-analysis-table


https://pubmed.ncbi.nlm.nih.gov/19396568


10. CONFLICT OF INTEREST

All members of the Muscle-invasive and Metastatic Bladder Cancer Guidelines Working Group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the European Association of Urology website: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/?type=panel.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organization and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

If a publisher and/or location is required, include:

References to individual guidelines should be structured in the following way:
Contributors’ names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.